id
stringlengths
22
37
tokens
sequence
ner_tags
sequence
texts
stringlengths
0
39.2k
2275286-01-Abstract-p01
[ "Hereditary", "nonpolyposis", "colorectal", "cancer", "(HNPCC)", "is", "an", "autosomal", "dominant", "syndrome.", "The", "National", "Cancer", "Institute", "(NCI)", "has", "recommended", "the", "Revised", "Bethesda", "guidelines", "for", "screening", "HNPCC.", "There", "has", "been", "a", "great", "deal", "of", "research", "on", "the", "value", "of", "these", "tests", "in", "other", "countries.", "However,", "literature", "about", "the", "Chinese", "population", "is", "scarce.", "Our", "objective", "is", "to", "detect", "and", "study", "microsatellite", "instability", "(MSI)", "and", "mismatch", "repair", "(MMR)", "gene", "germline", "mutation", "carriers", "among", "a", "Chinese", "population", "with", "colorectal", "cancer." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant syndrome. The National Cancer Institute (NCI) has recommended the Revised Bethesda guidelines for screening HNPCC. There has been a great deal of research on the value of these tests in other countries. However, literature about the Chinese population is scarce. Our objective is to detect and study microsatellite instability (MSI) and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
1360090-04-Discussion-p01
[ "In", "order", "to", "determine", "whether", "the", "characteristic", "clinicopathological", "features", "of", "tumors", "with", "BRAF", "mutation", "were", "due", "to", "their", "close", "association", "with", "MSI+", "and", "CIMP+,", "we", "stratified", "tumours", "according", "to", "these", "phenotypes.", "Despite", "having", "only", "9", "MSI-/BRAF", "mutant", "and", "5", "CIMP-/BRAF", "mutant", "tumors,", "the", "results", "showed", "that", "associations", "between", "BRAF", "mutation", "and", "the", "morphological", "properties", "of", "tumor-infiltrating", "infiltrating", "lymphocytes,", "poor", "histological", "grade", "and", "mucinous", "phenotype", "were", "retained", "(Tables", "3", "and", "4)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In order to determine whether the characteristic clinicopathological features of tumors with BRAF mutation were due to their close association with MSI+ and CIMP+, we stratified tumours according to these phenotypes. Despite having only 9 MSI-/BRAF mutant and 5 CIMP-/BRAF mutant tumors, the results showed that associations between BRAF mutation and the morphological properties of tumor-infiltrating infiltrating lymphocytes, poor histological grade and mucinous phenotype were retained (Tables 3 and 4).
1619718-04-Results-p01
[ "Note:", "no", "result", "for", "KRAS", "in", "one", "sessile", "serrated", "adenoma", "(SSA)", "and", "one", "adenomas", " ", "that", "had", "any", "BRAF", "mutations", "at", "all.", "Mutation", "frequencies", "for", "both", "KRAS", "and", "BRAF", "were", "distributed", "differently", "across", "the", "seven", "polyp", "groups", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Note: no result for KRAS in one sessile serrated adenoma (SSA) and one adenomas that had any BRAF mutations at all. Mutation frequencies for both KRAS and BRAF were distributed differently across the seven polyp groups (Table 1).
1557864-05-Discussion-p02
[ "Multiple", "differences", "between", "these", "studies", "could", "have", "caused", "the", "wide", "range", "in", "the", "MSI", "frequency", "(0–39%).", "One", "of", "these", "is", "the", "number", "and", "variety", "of", "microsatellite", "markers", "analyzed", "to", "determine", "the", "MSI.", "The", "NCI", "recommended", "five", "markers", "comprising", "the", "National", "Cancer", "Institute", "Consensus", "Panel", "(NCI-CP)", "for", "the", "detection", "of", "MSI,", "i.e.", "markers", "for", "the", "mononucleotide", "repeats", "BAT25", "and", "BAT26", "and", "the", "dinucleotide", "repeats", "D2S123,", "D5S346", "and", "D17S250", "[48].", "Table", "2", "shows", "per", "study", "the", "number", "of", "MS", "markers", "used", "and", "specifies", "how", "many", "of", "these", "are", "part", "of", "the", "NCI-CP.", "Interestingly,", "the", "studies", "that", "used", "all", "NCI-CP", "markers", "to", "determine", "the", "MS", "status", "also", "showed", "a", "wide", "range", "in", "MSI", "frequency", "(8–39%)", "which", "is", "similar", "to", "the", "overall", "range", "(0–39%).", "Therefore,", "the", "various", "MS", "markers", "used", "cannot", "be", "the", "sole", "cause", "for", "the", "wide", "range.", "Moreover,", "Gras", "et", "al.", "suggest", "that", "the", "reliability", "of", "the", "mononucleotide", "markers", "BAT25", "and", "BAT26", "is", "so", "high", "that", "most", "MSI", "can", "be", "predicted", "by", "evaluating", "these", "two", "markers", "exclusively", "[27],", "confirming", "the", "less", "stringent", "role", "for", "the", "various", "markers", "used", "for", "the", "analysis." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Multiple differences between these studies could have caused the wide range in the MSI frequency (0–39%). One of these is the number and variety of microsatellite markers analyzed to determine the MSI. The NCI recommended five markers comprising the National Cancer Institute Consensus Panel (NCI-CP) for the detection of MSI, i.e. markers for the mononucleotide repeats BAT25 and BAT26 and the dinucleotide repeats D2S123, D5S346 and D17S250 [48]. Table 2 shows per study the number of MS markers used and specifies how many of these are part of the NCI-CP. Interestingly, the studies that used all NCI-CP markers to determine the MS status also showed a wide range in MSI frequency (8–39%) which is similar to the overall range (0–39%). Therefore, the various MS markers used cannot be the sole cause for the wide range. Moreover, Gras et al. suggest that the reliability of the mononucleotide markers BAT25 and BAT26 is so high that most MSI can be predicted by evaluating these two markers exclusively [27], confirming the less stringent role for the various markers used for the analysis.
1619718-02-Introduction-p02
[ "This", "paper", "explores", "the", "possibility", "that", "the", "early", "evolution", "of", "colorectal", "cancer", " ", "is", "not", "limited", "to", "two", "essentially", "independent", "pathways,", "but", "often", "combines", "components", "of", "these", "pathways.", "Indeed,", "the", "successful", "‘fusion’", "of", "the", "hyperproliferation", "and", "crypt", "fission", "that", "characterize", "adenomas21", "with", "the", "inhibition", "of", "apoptosis", "that", "has", "been", "linked", "with", "serrated", "polyps22,23", "may", "generate", "lesions", "with", "enhanced", "aggressiveness", "MP", ")", "or", "could", "develop", "as", "de", "novo", "SA", "but", "through", "mechanisms", "shared", "with", "HPs.", "This", "proposal", "subsequently", "received", "strong", "support", "through", "the", "demonstration", "of", "molecular", "alterations", "common", "to", "both", "types", "of", "serrated", "polyp", ",", "notably", "mutation", "of", "BRAF", "and", "extensive", "DNA", "methylation.12", "This", "viewpoint", "was", "consolidated", "through", "the", "formal", "recognition", "of", "two", "largely", "independent", "pathways", "of", "colorectal", "tumorigenesis:", "(i)", "the", "traditional", "adenoma–carcinoma", "sequence", "associated", "with", "chomosomally", "unstable", "CRCs,13", "and", "(ii)", "the", "‘serrated", "pathway’", "culminating", "in", "CRCs", "chomosomally", "unstable", " ", "CRCs,13", "and", "(ii)", "the", "‘serrated", "pathway’", "culminating", "in", "CRCs", "with", "DNA", "microsatellite", "instability", "(MSI),", "mutation", "of", "BRAF", "and", "extensive", "DNA", "methylation.12,14–20" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 17, 18, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 19, 20, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
This paper explores the possibility that the early evolution of colorectal cancer is not limited to two essentially independent pathways, but often combines components of these pathways. Indeed, the successful ‘fusion’ of the hyperproliferation and crypt fission that characterize adenomas21 with the inhibition of apoptosis that has been linked with serrated polyps22,23 may generate lesions with enhanced aggressiveness MP ) or could develop as de novo SA but through mechanisms shared with HPs. This proposal subsequently received strong support through the demonstration of molecular alterations common to both types of serrated polyp , notably mutation of BRAF and extensive DNA methylation.12 This viewpoint was consolidated through the formal recognition of two largely independent pathways of colorectal tumorigenesis: (i) the traditional adenoma–carcinoma sequence associated with chomosomally unstable CRCs,13 and (ii) the ‘serrated pathway’ culminating in CRCs chomosomally unstable CRCs,13 and (ii) the ‘serrated pathway’ culminating in CRCs with DNA microsatellite instability (MSI), mutation of BRAF and extensive DNA methylation.12,14–20
1601966-03-Results-p01
[ "Evaluation", "of", "data", "set", "quality", "by", "tissue-wise", "hierarchical", "clustering" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Evaluation of data set quality by tissue-wise hierarchical clustering
1266026-03-Methods-p01
[ "For", "the", "SEER", "dataset,", "we", "also", "fit", "our", "model", "for", "cancer", "progression", "[11]", "with", "the", "inferential", "method", "described", "in", "reference", "12.", "This", "method", "does", "not", "require", "a", "life", "table,", "but", "unlike", "our", "method", "it", "does", "require", "information", "on", "all", "the", "cancer", "cancer", "cancers", "white", "rectum", "cancer", "MLH1", " ", "or", "MSH2", " ", "were", "detected", "by", "allelic", "specific", "PCR", "assays", "(for", "the", "two", "common", "Finnish", "MLH1", "cancers", "colorectal", " ", "cancers", "sampled", "from", "nine", "large", "regional", "hospitals", "in", "southeastern", "Finland", " ", "as", "part", "of", "a", "study", "to", "characterize", "genetic", "alterations", "in", "a", "well-defined", "population", "[9].", "The", "cancers", "represent", "approximately", "60%", "of", "all", "colorectal", " ", "cancers", "removed", "from", "this", "population", "in", "1994", "to", "1998", "[9].", "Germline", "mutations", "in", "MLH1", "or", "MSH2", "were", "detected", "by", "allelic", "specific", "PCR", "assays", "(for", "the", "two", "common", "Finnish", "MLH1", "germline", "mutations)", "or", "by", "direct", "genomic", "sequencing", "of", "coding", "exons", "[9].", "The", "data", "can", "be", "downloaded", "from", "the", "following", "website:", ".", "Approval", "for", "this", "research", "was", "obtained", "from", "the", "appropriate", "ethics", "committees,", "which", "are", "in", "compliance", "with", "the", "Helsinki", "Declaration." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 25, 3, 1, 21, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 9, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 25, 26, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
For the SEER dataset, we also fit our model for cancer progression [11] with the inferential method described in reference 12. This method does not require a life table, but unlike our method it does require information on all the cancer cancer cancers white rectum cancer MLH1 or MSH2 were detected by allelic specific PCR assays (for the two common Finnish MLH1 cancers colorectal cancers sampled from nine large regional hospitals in southeastern Finland as part of a study to characterize genetic alterations in a well-defined population [9]. The cancers represent approximately 60% of all colorectal cancers removed from this population in 1994 to 1998 [9]. Germline mutations in MLH1 or MSH2 were detected by allelic specific PCR assays (for the two common Finnish MLH1 germline mutations) or by direct genomic sequencing of coding exons [9]. The data can be downloaded from the following website: . Approval for this research was obtained from the appropriate ethics committees, which are in compliance with the Helsinki Declaration.
3034663-05-Discussion-p01
[ "The", "accelerated", "development", "of", "genetic", "counselling", "in", "cancer", "during", "the", "past", "few", "years", "is", "due", "to", "the", "feedback", "and", "interactive", "information", "sharing", "on", "genetic", "studies,", "clinical", "management", "and", "psychological", "issues", "in", "families", "with", "a", "high", "risk", "of", "cancer.", "Identification", "of", "deleterious", "variants", "in", "such", "families", "is", "essential", "for", "accurate", "assessment", "of", "individual", "risk", "and,", "if", "required,", "subsequent", "inclusion", "into", "a", "personalized", "surveillance", "programme." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The accelerated development of genetic counselling in cancer during the past few years is due to the feedback and interactive information sharing on genetic studies, clinical management and psychological issues in families with a high risk of cancer. Identification of deleterious variants in such families is essential for accurate assessment of individual risk and, if required, subsequent inclusion into a personalized surveillance programme.
3034663-03-Methods-p02
[ "MLH1", "promoter", "hypermethylation", "by", "Methylation", "Sensitive", "Multiplex", "Ligation-dependent", "Probe", "Amplification", "(MS-MLPA),", "and", "BRAF", "p.Val600Glu", "mutation", "by", "direct", "sequencing", "from", "tumor", "DNA", "was", "also", "assess", "when", "MLH1", "loss", "of", "expression", "was", "detected." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
MLH1 promoter hypermethylation by Methylation Sensitive Multiplex Ligation-dependent Probe Amplification (MS-MLPA), and BRAF p.Val600Glu mutation by direct sequencing from tumor DNA was also assess when MLH1 loss of expression was detected.
2275286-05-Discussion-p01
[ "At", "present,", "a", "number", "of", "publications", "have", "studied", "the", "value", "of", "the", "revised", "Bethesda", "criteria", "and", "the", "relevant", "diagnostic", "procedures", "[13,14].", "However,", "there", "has", "not", "been", "any", "systematic", "report", "on", "germline", "mutations", "of", "MMR", "genes", "in", "the", "Chinese", "population.", "Moreover,", "we", "found", "that", "research", "from", "some", "countries", "have", "results", "that,", "if", "applied", "to", "the", "NCI", "recommendations,", "may", "have", "resulted", "in", "a", "missed", "HNPCC", "family", "or", "low", "pick-up", "rate", "of", "HNPCC.", "In", "a", "study", "by", "Pinol", "et", "al.", "from", "Spain", "[13],", "287", "out", "of", "1222", "patients", "(23.5%)", "complied", "with", "the", "revised", "Bethesda", "standard.", "Ninety-one", "patients", "(7.4%)", "were", "MSI", "carriers,", "but", "only", "11", "patients", "(0.9%)", "had", "germline", "mutations", "of", "MSH2", "or", "MLH1.", "This", "means", "that", "among", "this", "group,", "only", "0.9%", "of", "patients", "could", "be", "diagnosed", "as", "HNPCC.", "In", "a", "study", "by", "Yearsley", "et", "al.", "[14],", "out", "of", "482", "US", "patients", "with", "colorectal", "cancers,", "87", "patients", "(18%)", "were", "MSI", "carriers", "and", "only", "12", "cases", "(2.5%)", "had", "MMR", "gene", "germline", "mutations.", "These", "results", "may", "be", "explained", "by", "different", "case", "selections", "and", "sensitivity", "of", "the", "tests", "used.", "On", "the", "other", "hand,", "in", "their", "study", "of", "HNPCC", "related", "tumors", "in", "young", "patients", "(<50", "years", "old),", "Niessen", "et", "al.", "[15]", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "in", "MSI", "carriers", "was", "82%.", "In", "our", "146", "patients", "with", "colorectal", "cancers,", "34", "patients", "(23.3%)", "had", "MSI", "colorectal", "cancer.", "This", "is", "comparable", "to", "the", "studies", "by", "Pinol", "et", "al.", "[13]", "and", "Yearsley", "et", "al.", "[16].", "Wong", "et", "al.", "[17]", "showed", "that", "in", "the", "case", "of", "sporadic", "endometrial", "carcinoma,", "MSI", "endometrial", "carcinoma", "accounted", "for", "26%", "of", "patients.", "Our", "results", "showed", "that", "there", "were", "15", "(10.3%)", "CRCs", "with", "MSI-L", "and", "19", "(13.0%)", "CRCs", "with", "MSL-H,", "respectively.", "Lamberti", "et", "al.", "[18]", "reported", "that", "MSI-L", "and", "MSI-H", "accounted", "for", "6%", "and", "17%,", "respectively,", "of", "German", "patients.", "These", "results", "are", "similar", "to", "ours.", "Unexpectedly,", "in", "the", "present", "study,", "the", "age", "of", "patients", "with", "MSS", "colorectal", "cancers", "(60", "yrs)", "was", "similar", "to", "the", "age", "of", "patients", "with", "MSI-H", "(61", "yrs).", "In", "contrast,", "the", "average", "age", "of", "patients", "with", "MSI-L", "colorectal", "cancer", "was", "71,", "which", "was", "quite", "different", "from", "the", "reports", "of", "other", "research", "groups", "[13,15,18].", "In", "a", "study", "of", "1263", "patients", "with", "colorectal", "cancers,", "Benatti", "et", "al.", "[19]", "found", "that", "those", "who", "were", "MSI", "carriers", "tended", "to", "have", "mucinous", "and", "right", "colonic", "tumours.", "Noda", "et", "al.", "[20]", "also", "found", "that", "MSI", "carriers", "have", "more", "right", "colonic", "tumors.", "However,", "in", "our", "study,", "tumors", "in", "the", "MSI", "group", "were", "most", "commonly", "located", "at", "the", "rectum,", "and", "mucinous", "carcinoma", "was", "not", "the", "most", "common", "pathological", "type,", "as", "it", "only", "accounted", "for", "29%.", "Interestingly,", "patients", "in", "our", "MSI-L", "group", "were", "older", "than", "the", "MSS", "group.", "The", "reason", "for", "these", "findings", "is", "uncertain.", "Bettstetter", "et", "al.", "[20]", "reported", "that", "the", "average", "age", "of", "MSI", "CRCs", "with", "MLH1", "negative", "staining", "was", "80", "yrs,", "which", "was", "similar", "to", "our", "results.", "Most", "of", "these", "MSI", "CRCs", "were", "caused", "by", "MLH1", "promoter", "hypermethylation.", "In", "our", "group,", "out", "of", "34", "MSI", "CRCs,", "19", "CRCs", "(55.9%)", "were", "hypermethylated", "at", "the", "MLH1", "promoter,", "which", "accounted", "for", "73.7%", "of", "MSI-H", "CRCs", "and", "33.3%", "of", "MSI", "CRCs.", "Anacleto", "et", "al.", "[21]", "reported", "that", "8", "out", "of", "15", "MSI", "CRCs", "had", "MLH1", "promoter", "hypermethylation,", "which", "was", "similar", "to", "our", "results.", "Kim", "et", "al.", "[10]", "found", "that", "in", "MSI-H", "gastric", "cancers,", "the", "MLH1", "hypermethylation", "occurred", "in", "89%", "of", "patients.", "Bettstetter", "et", "al.", "[20]", "showed", "that", "all", "sporadic", "MSI-H", "CRCs", "were", "hypermethylated", "at", "the", "MLH1", "promoter.", "These", "results", "were", "similar", "to", "ours.", "Fourteen", "out", "of", "16", "MLH1", "negatively", "staining", "CRCs", "were", "hypermethylated", "at", "the", "MLH1promoter.", "Mutation", "analysis", "revealed", "that", "8", "patients", "(23.5%)", "had", "MMR", "gene", "germline", "mutations", "out", "of", "34", "MSI", "patients.", "Five", "patients", "had", "MSH2", "mutations", "and", "3", "had", "MSH6", "mutations,", "while", "no", "population", ".", "Moreover,", "we", "found", "that", "research", "from", "some", "countries", "have", "results", "that,", "if", "applied", "to", "the", "NCI", "recommendations,", "may", "have", "resulted", "in", "a", "missed", "HNPCC", "family", "or", "low", "pick-up", "rate", "of", "HNPCC.", "In", "a", "study", "by", "Pinol", "et", "al.", "from", "Spain", " ", "[13],", "287", "out", "of", "1222", "patients", "(23.5%)", "complied", "with", "the", "revised", "Bethesda", "standard.", "Ninety-one", "patients", "(7.4%)", "were", "MSI", "carriers,", "but", "only", "11", "patients", "(0.9%)", "had", "germline", "mutations", "of", "MSH2", "or", "MLH1.", "This", "means", "that", "among", "this", "group,", "only", "0.9%", "of", "patients", "could", "be", "diagnosed", "as", "HNPCC.", "In", "a", "study", "by", "Yearsley", "et", "al.", "[14],", "out", "of", "482", "US", "patients", "with", "colorectal", "cancers,", "87", "patients", "(18%)", "were", "MSI", "carriers", "and", "only", "12", "cases", "(2.5%)", "had", "MMR", "gene", "germline", "mutations.", "These", "results", "may", "be", "explained", "by", "different", "case", "selections", "and", "sensitivity", "of", "the", "tests", "used.", "On", "the", "other", "hand,", "in", "their", "study", "of", "HNPCC", "related", "tumors", "in", "young", "patients", "(<50", "years", "old),", "Niessen", "et", "al.", "[15]", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "in", "MSI", "carriers", "was", "82%.", "In", "our", "146", "patients", "with", "colorectal", "cancers,", "34", "patients", "(23.3%)", "had", "MSI", "colorectal", "cancer", "MSI", "carriers", ",", "but", "only", "11", "patients", "(0.9%)", "had", "germline", "mutations", " ", "of", "MSH2", "or", "MLH1.", "This", "means", "that", "among", "this", "group,", "only", "0.9%", "of", "patients", "could", "be", "diagnosed", "as", "HNPCC.", "In", "a", "study", "by", "Yearsley", "et", "al.", "[14],", "out", "of", "482", "US", "patients", "with", "colorectal", "cancers,", "87", "patients", "(18%)", "were", "MSI", "carriers", "and", "only", "12", "cases", "(2.5%)", "had", "MMR", "gene", "germline", "mutations.", "These", "results", "may", "be", "explained", "by", "different", "case", "selections", "and", "sensitivity", "of", "the", "tests", "used.", "On", "the", "other", "hand,", "in", "their", "study", "of", "HNPCC", "related", "tumors", "in", "young", "patients", "(<50", "years", "old),", "Niessen", "et", "al.", "[15]", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "in", "MSI", "carriers", "was", "82%.", "In", "our", "146", "patients", "with", "colorectal", "cancers,", "34", "patients", "(23.3%)", "had", "MSI", "colorectal", "cancer.", "This", "is", "comparable", "to", "the", "studies", "by", "Pinol", "et", "al.", "[13]", "and", "Yearsley", "et", "al.", "[16].", "Wong", "et", "al.", "[17]", "showed", "that", "in", "the", "case", "of", "sporadic", "endometrial", "carcinoma,", "MSI", "endometrial", "carcinoma", "accounted", "for", "26%", "of", "patients.", "Our", "results", "showed", "that", "there", "were", "15", "(10.3%)", "CRCs", "with", "MSI-L", "and", "19", "(13.0%)", "CRCs", "with", "MSL-H,", "respectively.", "Lamberti", "et", "al.", "[18]", "reported", "that", "MSI-L", "and", "MSI-H", "accounted", "for", "6%", "and", "17%,", "respectively,", "of", "German", "patients.", "These", "results", "are", "similar", "to", "ours.", "Unexpectedly,", "in", "the", "present", "study,", "the", "age", "of", "patients", "with", "MSS", "colorectal", "cancers", " ", "(60", "yrs)", "was", "similar", "to", "the", "age", "of", "patients", "with", "MSI-H", "(61", "yrs).", "In", "contrast,", "the", "average", "age", "of", "patients", "with", "MSI-L", "colorectal", "cancer", "was", "71,", "which", "was", "quite", "different", "from", "the", "reports", "of", "other", "research", "groups", "[13,15,18].", "In", "a", "study", "of", "1263", "patients", "with", "colorectal", "cancers,", "Benatti", "et", "al.", "[19]", "found", "that", "those", "who", "were", "MSI", "carriers", "tended", "to", "have", "mucinous", "and", "right", "colonic", "tumours.", "Noda", "et", "al.", "[20]", "also", "found", "that", "MSI", "carriers", "have", "more", "right", "colonic", "tumors.", "However,", "in", "our", "study,", "tumors", "in", "the", "MSI", "group", "were", "most", "commonly", "located", "at", "the", "rectum,", "and", "mucinous", " ", "carcinoma", "was", "not", "the", "most", "common", "pathological", "type,", "as", "it", "only", "accounted", "for", "29%.", "Interestingly,", "patients", "in", "our", "MSI-L", "group", "were", "older", "than", "the", "MSS", "group.", "The", "reason", "for", "these", "findings", "is", "uncertain.", "Bettstetter", "et", "al.", "[20]", "reported", "that", "the", "average", "age", "of", "MSI", "CRCs", "with", "MLH1", "negative", "staining", "was", "80", "yrs,", "which", "was", "similar", "to", "our", "results.", "Most", "of", "these", "MSI", "CRCs", "were", "caused", "by", "MLH1", "promoter", "hypermethylation.", "In", "our", "group,", "out", "of", "34", "MSI", "CRCs,", "19", "CRCs", "(55.9%)", "were", "hypermethylated", "at", "the", "MLH1", "promoter,", "which", "accounted", "for", "73.7%", "of", "MSI-H", "CRCs", "and", "33.3%", "of", "MSI", "CRCs.", "Anacleto", "et", "al.", "[21]", "reported", "that", "8", "out", "of", "15", "MSI", "CRCs", "had", "MLH1", "promoter", "hypermethylation,", "which", "was", "similar", "to", "our", "results.", "Kim", "et", "al.", "[10]", "found", "that", "in", "MSI-H", "gastric", "cancers,", "the", "MLH1", "hypermethylation", "occurred", "in", "89%", "of", "patients.", "Bettstetter", "et", "al.", "[20]", "showed", "that", "all", "sporadic", "MSI-H", "CRCs", "were", "hypermethylated", "at", "the", "MLH1", "promoter.", "These", "results", "were", "similar", "to", "ours.", "Fourteen", "out", "of", "16", "MLH1", "negatively", "staining", "CRCs", "were", "hypermethylated", "at", "the", "MLH1promoter.", "Mutation", "analysis", "revealed", "that", "8", "patients", "(23.5%)", "had", "MMR", "gene", "germline", "mutations", "out", "of", "34", "MSI", "patients.", "Five", "patients", "had", "MSH2", "mutations", "and", "3", "had", "MSH6", "mutations,", "while", "no", "MLH1", "mutation", "was", "found.", "There", "were", "2", "and", "6", "patients", "who", "had", "mutations", "in", "MSH2", "and", "MSH6", "in", "the", "MSI-L", "and", "MSI-H", "groups,", "respectively.", "Yearsley", "et", "al.", "[15],", "in", "their", "study", "of", "87", "patients", "with", "MSI", "colorectal", "cancers,", "found", "12", "patients", "(13.8%)", "with", "MLH1", "and", "MSH2", "germline", "mutations.", "Niessen", "et", "al.", "[16],", "however,", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "was", "82%", "33.3%", "colorectal", "cancers", "US", " ", "patients", "with", "colorectal", " ", "cancers,", "87", "patients", "(18%)", "were", "MSI", "carriers", "and", "only", "12", "cases", "(2.5%)", "had", "MMR", "gene", "germline", "mutations.", "These", "results", "may", "be", "explained", "by", "different", "case", "selections", "and", "sensitivity", "of", "the", "tests", "used.", "On", "the", "other", "hand,", "in", "their", "study", "of", "HNPCC", "related", "tumors", "in", "young", "patients", "(<50", "years", "old),", "Niessen", "et", "al.", "[15]", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "in", "MSI", "carriers", "was", "82%.", "In", "our", "146", "patients", "with", "colorectal", "cancers,", "34", "patients", "(23.3%)", "had", "MSI", "colorectal", "cancer.", "This", "is", "comparable", "to", "the", "studies", "by", "Pinol", "et", "al.", "[13]", "and", "Yearsley", "et", "al.", "[16].", "Wong", "et", "al.", "[17]", "showed", "that", "in", "the", "case", "of", "sporadic", "endometrial", "carcinoma,", "MSI", "endometrial", "carcinoma", "accounted", "for", "26%", "of", "patients.", "Our", "results", "showed", "that", "there", "were", "15", "(10.3%)", "CRCs", "with", "MSI-L", "and", "19", "(13.0%)", "CRCs", "with", "MSL-H,", "respectively.", "Lamberti", "et", "al.", "[18]", "reported", "that", "MSI-L", "and", "MSI-H", "accounted", "for", "6%", "and", "17%,", "respectively,", "of", "German", "patients.", "These", "results", "are", "similar", "to", "ours.", "Unexpectedly,", "in", "the", "present", "study,", "the", "age", "of", "patients", "with", "MSS", "colorectal", "cancers", "(60", "yrs)", "was", "similar", "to", "the", "age", "of", "patients", "with", "MSI-H", "(61", "yrs).", "In", "contrast,", "the", "average", "age", "of", "patients", "with", "MSI-L", "colorectal", "cancer", "was", "71,", "which", "was", "quite", "different", "from", "the", "reports", "of", "other", "research", "groups", "[13,15,18].", "In", "a", "study", "of", "1263", "patients", "with", "colorectal", "cancers,", "Benatti", "et", "al.", "[19]", "found", "that", "those", "who", "were", "MSI", "carriers", "tended", "to", "have", "mucinous", "and", "right", "colonic", "tumours.", "Noda", "et", "al.", "[20]", "also", "found", "that", "MSI", "carriers", "have", "more", "right", "colonic", "tumors.", "However,", "in", "our", "study,", "tumors", "in", "the", "MSI", "group", "were", "most", "commonly", "located", "at", "the", "rectum,", "and", "mucinous", "carcinoma", "was", "not", "the", "most", "common", "pathological", "type,", "as", "it", "only", "accounted", "for", "29%.", "Interestingly,", "patients", "in", "our", "MSI-L", "group", "were", "older", "than", "the", "MSS", "group.", "The", "reason", "for", "these", "findings", "is", "uncertain.", "Bettstetter", "et", "al.", "[20]", "reported", "that", "the", "average", "age", "of", "MSI", "CRCs", "with", "MLH1", "negative", "staining", "was", "80", "yrs,", "which", "was", "similar", "to", "our", "results.", "Most", "of", "these", "MSI", "CRCs", "were", "caused", "by", "MLH1", "promoter", "hypermethylation.", "In", "our", "group,", "out", "of", "34", "MSI", "CRCs,", "19", "CRCs", "(55.9%)", "were", "hypermethylated", "at", "the", "MLH1", "promoter,", "which", "accounted", "for", "73.7%", "of", "MSI-H", "CRCs", "and", "33.3%", "of", "MSI", " ", "CRCs", ".", "Anacleto", "et", "al.", "[21]", "reported", "that", "8", "out", "of", "15", " ", "MSI", " ", "CRCs", " ", "had", "MLH1", "promoter", "hypermethylation", ",", "which", "was", "similar", "to", "our", "results.", "Kim", "et", "al.", "[10]", "found", "that", "in", "MSI-H", "gastric", "cancers,", "the", "MLH1", "hypermethylation", "occurred", "in", "89%", "of", "patients.", "Bettstetter", "et", "al.", "[20]", "showed", "that", "all", "sporadic", "MSI-H", "CRCs", "were", "hypermethylated", "at", "the", "MLH1", "promoter.", "These", "results", "were", "similar", "to", "ours.", "Fourteen", "out", "of", "16", "MLH1", "negatively", "staining", "CRCs", "were", "hypermethylated", "at", "the", "MLH1promoter.", "Mutation", "analysis", "revealed", "that", "8", "patients", "(23.5%)", "had", "MMR", "gene", "germline", "mutations", "out", "of", "34", "MSI", "patients.", "Five", "patients", "had", "MSH2", "mutations", "and", "3", "had", "MSH6", "mutations,", "while", "no", "MLH1", "mutation", "was", "found.", "There", "were", "2", "and", "6", "patients", "who", "had", "mutations", "in", "MSH2", "and", "MSH6", "in", "the", "MSI-L", "and", "MSI-H", "groups,", "respectively.", "Yearsley", "et", "al.", "[15],", "in", "their", "study", "of", "87", "patients", "with", "MSI", "colorectal", "cancers,", "found", "12", "patients", "(13.8%)", "with", "MLH1", "and", "MSH2", "germline", "mutations.", "Niessen", "et", "al.", "[16],", "however,", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "was", "82%", "in", "the", "young", "age", "group", "(<50", "years", "old).", "This", "was", "quite", "different", "from", "our", "group.", "This", "difference", "might", "be", "due", "to", "different", "case", "87", " ", "patients", "(18%)", "were", "MSI", "carriers", "and", "only", "12", "cases", "(2.5%)", "had", "MMR", "gene", "germline", "mutations.", "These", "results", "may", "be", "explained", "by", "different", "case", "selections", "and", "sensitivity", "of", "the", "tests", "used.", "On", "the", "other", "hand,", "in", "their", "study", "of", "HNPCC", "related", "tumors", "in", "young", "patients", "(<50", "years", "old),", "Niessen", "et", "al.", "[15]", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "in", "MSI", "carriers", "was", "82%.", "In", "our", "146", "patients", "with", "colorectal", "cancers,", "34", "patients", "(23.3%)", "had", "MSI", "colorectal", "cancer.", "This", "is", "comparable", "to", "the", "studies", "by", "Pinol", "et", "al.", "[13]", "and", "Yearsley", "et", "al.", "[16].", "Wong", "et", "al.", "[17]", "showed", "that", "in", "the", "case", "of", "sporadic", "endometrial", "carcinoma,", "MSI", "endometrial", "carcinoma", "accounted", "for", "26%", "of", "patients.", "Our", "results", "showed", "that", "there", "were", "15", "(10.3%)", "CRCs", "with", "MSI-L", "and", "19", "(13.0%)", "CRCs", "with", "MSL-H,", "respectively.", "Lamberti", "et", "al.", "[18]", "reported", "that", "MSI-L", "and", "MSI-H", "accounted", "for", "6%", "and", "17%,", "respectively,", "of", "German", "patients.", "These", "results", "are", "similar", "to", "ours.", "Unexpectedly,", "in", "the", "present", "study,", "the", "age", "of", "patients", "with", "MSS", "colorectal", "cancers", "(60", "yrs)", "was", "similar", "to", "the", "age", "of", "patients", "with", "MSI-H", "(61", "yrs).", "In", "contrast,", "the", "average", "age", "of", "patients", "with", "MSI-L", "colorectal", "cancer", "was", "71,", "which", "was", "quite", "different", "from", "the", "reports", "of", "other", "research", "groups", "[13,15,18].", "In", "a", "study", "of", "1263", "patients", "with", "colorectal", "cancers,", "Benatti", "et", "al.", "[19]", "found", "that", "those", "who", "were", "MSI", "carriers", "tended", "to", "have", "mucinous", "and", "right", "colonic", "tumours.", "Noda", "et", "al.", "[20]", "also", "found", "that", "MSI", "carriers", "have", "more", "right", "colonic", "tumors.", "However,", "in", "our", "study,", "tumors", "in", "the", "MSI", "group", "were", "most", "commonly", "located", "at", "the", "rectum,", "and", "mucinous", "carcinoma", "was", "not", "the", "most", "common", "pathological", "type,", "as", "it", "only", "accounted", "for", "29%.", "Interestingly,", "patients", "in", "our", "MSI-L", "group", "were", "older", "than", "the", "MSS", "group.", "The", "reason", "for", "these", "findings", "is", "uncertain.", "Bettstetter", "et", "al.", "[20]", "reported", "that", "the", "average", "age", "of", "MSI", "CRCs", "with", "MLH1", "negative", "staining", "was", "80", "yrs,", "which", "was", "similar", "to", "our", "results.", "Most", "of", "these", "MSI", "CRCs", "were", "caused", "by", "MLH1", "promoter", "hypermethylation.", "In", "our", "group,", "out", "of", "34", "MSI", "CRCs,", "19", "CRCs", "(55.9%)", "were", "hypermethylated", "at", "the", "MLH1", "promoter,", "which", "accounted", "for", "73.7%", "of", "MSI-H", "CRCs", "and", "33.3%", "of", "MSI", "CRCs.", "Anacleto", "et", "al.", "[21]", "reported", "that", "8", "out", "of", "15", "MSI", "CRCs", "had", "MLH1", "promoter", "hypermethylation,", "which", "was", "similar", "to", "our", "results.", "Kim", "et", "al.", "[10]", "found", "that", "in", "MSI-H", "gastric", "2.5%", ")", "had", "MMR", "gene", "germline", "mutations.", "These", "results", "may", "be", "explained", "by", "different", "case", "selections", "and", "sensitivity", "of", "the", "tests", "used.", "On", "the", "other", "hand,", "in", "their", "study", "of", "HNPCC", "related", "tumors", "in", "young", "patients", "(<50", "years", "old),", "Niessen", "et", "al.", "[15]", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "in", "MSI", "carriers", "was", "82%.", "In", "our", "146", "patients", "with", "colorectal", "cancers,", "34", "patients", "(23.3%)", "had", "MSI", "colorectal", "cancer.", "This", "is", "comparable", "to", "the", "studies", "by", "Pinol", "et", "al.", "[13]", "and", "Yearsley", "et", "al.", "[16].", "Wong", "et", "al.", "[17]", "showed", "that", "in", "the", "case", "of", "sporadic", "endometrial", "carcinoma,", "MSI", "endometrial", "carcinoma", "accounted", "for", "26%", "of", "patients.", "Our", "results", "showed", "that", "there", "were", "15", "(10.3%)", "CRCs", "with", "MSI-L", "and", "19", "(13.0%)", "CRCs", "with", "MSL-H,", "respectively.", "Lamberti", "et", "al.", "[18]", "reported", "that", "MSI-L", "and", "MSI-H", "accounted", "for", "6%", "and", "17%,", "respectively,", "of", "German", "patients.", "These", "results", "are", "similar", "to", "ours.", "Unexpectedly,", "in", "the", "present", "study,", "the", "age", "of", "patients", "with", "MSS", "colorectal", "cancers", "(60", "yrs)", "was", "similar", "to", "the", "age", "of", "patients", "with", "MSI-H", "(61", "yrs).", "In", "contrast,", "the", "average", "age", "of", "patients", "with", "MSI-L", "colorectal", "cancer", "was", "71,", "which", "was", "quite", "different", "from", "the", "reports", "of", "other", "research", "groups", "[13,15,18].", "In", "a", "study", "of", "1263", "patients", "with", "colorectal", "cancers,", "Benatti", "et", "al.", "[19]", "found", "that", "those", "who", "were", "MSI", "carriers", "tended", "to", "have", "mucinous", "and", "right", "colonic", "tumours.", "Noda", "et", "al.", "[20]", "also", "found", "that", "MSI", "carriers", "have", "more", "right", "colonic", "tumors.", "However,", "in", "our", "study,", "tumors", "in", "the", "MSI", "group", "were", "most", "commonly", "located", "at", "the", "rectum,", "and", "mucinous", "carcinoma", "was", "not", "the", "most", "common", "pathological", "type,", "as", "it", "only", "accounted", "for", "29%.", "Interestingly,", "patients", "in", "our", "MSI-L", "group", "were", "older", "than", "the", "MSS", "group.", "The", "reason", "for", "these", "findings", "is", "uncertain.", "Bettstetter", "et", "al.", "[20]", "reported", "that", "the", "average", "age", "of", "MSI", "CRCs", "with", "MLH1", "negative", "staining", "was", "80", "yrs,", "which", "was", "similar", "to", "our", "results.", "Most", "of", "these", "MSI", "CRCs", "were", "caused", "by", "MLH1", "promoter", "hypermethylation.", "In", "our", "group,", "out", "of", "34", "cancers", ",", "87", "patients", "(18%)", "were", "MSI", "carriers", "and", "only", "12", "cases", "(2.5%)", "had", "MMR", "gene", "germline", "mutations.", "These", "results", "may", "be", "explained", "by", "different", "case", "selections", "and", "sensitivity", "of", "the", "tests", "used.", "On", "the", "other", "hand,", "in", "their", "study", "of", "HNPCC", "related", "tumors", "in", "young", "patients", "(<50", "years", "old),", "Niessen", "et", "al.", "[15]", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "in", "MSI", "carriers", "was", "82%.", "In", "our", "146", "patients", "with", "colorectal", "cancers,", "34", "patients", "(23.3%)", "had", "MSI", "colorectal", "cancer.", "This", "is", "comparable", "to", "the", "studies", "by", "Pinol", "et", "al.", "[13]", "and", "Yearsley", "et", "al.", "[16].", "Wong", "et", "al.", "[17]", "showed", "that", "in", "the", "case", "of", "sporadic", "endometrial", "carcinoma,", "MSI", "endometrial", "carcinoma", "accounted", "for", "26%", "of", "patients.", "Our", "results", "showed", "that", "there", "were", "15", "(10.3%)", "CRCs", "with", "MSI-L", "and", "19", "(13.0%)", "CRCs", "with", "MSL-H,", "respectively.", "Lamberti", "et", "al.", "[18]", "reported", "that", "MSI-L", "and", "MSI-H", "accounted", "for", "6%", "and", "17%,", "respectively,", "of", "German", "patients.", "These", "results", "are", "similar", "to", "ours.", "Unexpectedly,", "in", "the", "present", "study,", "the", "age", "of", "patients", "with", "MSS", "colorectal", "cancers", "(60", "yrs)", "was", "similar", "to", "the", "age", "of", "patients", "with", "MSI-H", "(61", "yrs).", "In", "contrast,", "the", "average", "age", "of", "patients", "with", "MSI-L", "colorectal", "cancer", "was", "71,", "which", "was", "quite", "different", "from", "the", "reports", "of", "other", "research", "groups", "[13,15,18].", "In", "a", "study", "of", "1263", "patients", "with", "colorectal", "cancers,", "Benatti", "et", "al.", "[19]", "found", "that", "those", "who", "were", "MSI", "carriers", "tended", "to", "have", "mucinous", "and", "right", "colonic", "tumours.", "Noda", "et", "al.", "[20]", "also", "found", "that", "MSI", "carriers", "have", "more", "right", "colonic", "tumors.", "However,", "in", "our", "study,", "tumors", "in", "the", "MSI", "group", "were", "most", "commonly", "located", "at", "the", "rectum,", "and", "mucinous", "carcinoma", "was", "not", "the", "most", "common", "pathological", "type,", "as", "it", "only", "accounted", "for", "29%.", "Interestingly,", "patients", "in", "our", "MSI-L", "group", "were", "older", "than", "the", "MSS", "group.", "The", "reason", "for", "these", "findings", "is", "uncertain.", "Bettstetter", "et", "al.", "[20]", "reported", "that", "the", "average", "age", "of", "MSI", "CRCs", "with", "MLH1", "negative", "staining", "was", "80", "yrs,", "which", "was", "similar", "to", "our", "results.", "Most", "of", "these", "MSI", "CRCs", "were", "caused", "by", "MLH1", "promoter", "hypermethylation.", "In", "our", "group,", "out", "of", "34", "MSI", "CRCs,", "19", "CRCs", "(55.9%)", "were", "hypermethylated", "at", "the", "MLH1", "promoter,", "which", "accounted", "for", "73.7%", "of", "MSI-H", "CRCs", "and", "33.3%", "of", "MSI", "CRCs.", "Anacleto", "et", "al.", "[21]", "reported", "that", "8", "out", "of", "15", "MSI", "CRCs", "had", "MLH1", "promoter", "hypermethylation,", "which", "was", "similar", "to", "our", "results.", "Kim", "et", "al.", "[10]", "found", "that", "in", "MSI-H", "gastric", "cancers,", "the", "MLH1", "hypermethylation", "occurred", "in", "89%", "of", "patients.", "Bettstetter", "et", "al.", "[20]", "showed", "that", "all", "sporadic", "MSI-H", "CRCs", "were", "hypermethylated", "at", "the", "MLH1", "promoter.", "These", "results", "were", "similar", "to", "ours.", "Fourteen", "out", "of", "16", "MLH1", "negatively", "staining", "CRCs", "were", "hypermethylated", "at", "the", "MLH1promoter.", "Mutation", "analysis", "revealed", "that", "8", "patients", "(23.5%)", "had", "MMR", "gene", "germline", "mutations", "out", "of", "34", "MSI", "patients.", "Five", "patients", "had", "MSH2", "mutations", "and", "3", "had", "MSH6", "mutations,", "while", "no", "MLH1", "mutation", "was", "found.", "There", "were", "2", "and", "6", "patients", "who", "had", "mutations", "in", "MSH2", "and", "MSH6", "in", "the", "MSI-L", "and", "MSI-H", "groups,", "respectively.", "Yearsley", "et", "al.", "[15],", "in", "their", "study", "of", "87", "patients", "with", "MSI", "colorectal", "cancers,", "found", "12", "patients", "(13.8%)", "with", "MLH1", "and", "MSH2", "germline", "mutations.", "Niessen", "et", "al.", "[16],", "however,", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "was", "82%", "in", "the", "young", "age", "group", "(<50", "years", "old).", "This", "was", "quite", "different", "from", "our", "group.", "This", "difference", "might", "be", "due", "to", "different", "case", "selections", "of", "the", "two", "groups.", "Our", "study", "was", "more", "representative", "of", "the", "patient", "population", "because", "it", "was", "a", "successive", "cohort", "study.", "Most", "importantly,", "the", "above", "differences", "may", "also", "be", "explained", "by", "underlying", "differences", "in", "genetic", "background", "between", "Chinese", "and", "Western", "populations", "0.9%", "23.5%", ")", "complied", "with", "the", "revised", "Bethesda", "standard.", "Ninety-one", "patients", "(7.4%)", "were", "MSI", "carriers,", "but", "only", "11", "patients", "(0.9%)", "had", "germline", "mutations", "of", "MSH2", "or", "MLH1.", "This", "means", "that", "among", "this", "group,", "only", "0.9%", "of", "patients", "could", "be", "diagnosed", "as", "HNPCC.", "In", "a", "study", "by", "Yearsley", "et", "al.", "[14],", "out", "of", "482", "US", "patients", "with", "colorectal", "cancers,", "87", "patients", "(18%)", "were", "MSI", "carriers", "and", "only", "12", "cases", "(2.5%)", "had", "MMR", "gene", "germline", "mutations.", "These", "results", "may", "be", "explained", "by", "different", "case", "selections", "and", "sensitivity", "of", "the", "tests", "used.", "On", "the", "other", "hand,", "in", "their", "study", "of", "HNPCC", "related", "tumors", "in", "young", "patients", "(<50", "years", "old),", "Niessen", "et", "al.", "[15]", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "in", "MSI", "carriers", "was", "82%.", "In", "our", "146", "patients", "with", "colorectal", "cancers,", "34", "patients", "(23.3%)", "had", "MSI", "colorectal", "cancer.", "This", "is", "comparable", "to", "the", "studies", "by", "Pinol", "et", "al.", "[13]", "and", "Yearsley", "et", "al.", "[16].", "Wong", "et", "al.", "[17]", "showed", "that", "in", "the", "case", "of", "sporadic", "endometrial", "carcinoma,", "MSI", "endometrial", "carcinoma", "accounted", "for", "26%", "of", "patients.", "Our", "results", "showed", "that", "there", "were", "15", "(10.3%)", "CRCs", "with", "MSI-L", "and", "19", "(13.0%)", "CRCs", "with", "MSL-H,", "respectively.", "Lamberti", "et", "al.", "[18]", "reported", "that", "MSI-L", "and", "MSI-H", "accounted", "for", "6%", "and", "17%,", "respectively,", "of", "German", "patients.", "These", "results", "are", "similar", "to", "ours.", "Unexpectedly,", "in", "the", "present", "study,", "the", "age", "of", "patients", "with", "MSS", "colorectal", "cancers", "(60", "yrs)", "was", "similar", "to", "the", "age", "of", "patients", "with", "MSI-H", "(61", "yrs).", "In", "contrast,", "the", "average", "age", "of", "patients", "with", "MSI-L", "colorectal", "cancer", "was", "71,", "which", "was", "quite", "different", "from", "the", "reports", "of", "other", "research", "groups", "[13,15,18].", "In", "a", "study", "of", "1263", "patients", "with", "colorectal", "cancers,", "Benatti", "et", "al.", "[19]", "found", "that", "those", "who", "were", "MSI", "carriers", "tended", "to", "have", "mucinous", "and", "right", "colonic", "tumours.", "Noda", "et", "al.", "[20]", "also", "found", "that", "MSI", "carriers", "have", "more", "right", "colonic", "tumors.", "However,", "in", "our", "study,", "tumors", "in", "the", "MSI", "group", "were", "most", "commonly", "located", "at", "the", "rectum,", "and", "mucinous", "carcinoma", "was", "not", "the", "most", "common", "pathological", "type,", "as", "it", "only", "accounted", "for", "29%.", "Interestingly,", "patients", "in", "our", "MSI-L", "group", "were", "older", "than", "the", "MSS", "group.", "The", "reason", "for", "these", "findings", "is", "uncertain.", "Bettstetter", "et", "al.", "[20]", "reported", "that", "the", "average", "age", "of", "MSI", "CRCs", "with", "MLH1", "negative", "staining", "was", "80", "yrs,", "which", "was", "similar", "to", "our", "results.", "Most", "of", "these", "MSI", "CRCs", "were", "caused", "by", "MLH1", "promoter", "hypermethylation.", "In", "our", "group,", "out", "of", "34", "MSI", "CRCs,", "19", "CRCs", "(55.9%)", "were", "hypermethylated", "at", "the", "MLH1", "promoter,", "which", "accounted", "for", "73.7%", "of", "MSI-H", "CRCs", "and", "33.3%", "of", "MSI", "CRCs.", "Anacleto", "et", "al.", "[21]", "reported", "that", "8", "out", "of", "15", "MSI", "CRCs", "had", "MLH1", "promoter", "hypermethylation,", "which", "was", "similar", "to", "our", "results.", "Kim", "et", "al.", "[10]", "found", "that", "in", "MSI-H", "gastric", "cancers,", "the", "MLH1", "hypermethylation", "occurred", "in", "89%", "of", "patients.", "Bettstetter", "et", "al.", "[20]", "showed", "that", "all", "sporadic", "MSI-H", "CRCs", "were", "hypermethylated", "at", "the", "MLH1", "promoter.", "These", "results", "were", "similar", "to", "ours.", "Fourteen", "out", "of", "16", "MLH1", "negatively", "staining", "CRCs", "were", "hypermethylated", "at", "the", "MLH1promoter.", "Mutation", "analysis", "revealed", "that", "8", "patients", "(23.5%)", "had", "MMR", "gene", "germline", "mutations", "out", "of", "34", "MSI", "patients.", "Five", "patients", "had", "MSH2", "mutations", "and", "3", "had", "MSH6", "mutations,", "while", "no", "MLH1", "mutation", "was", "found.", "There", "were", "2", "and", "6", "patients", "who", "had", "mutations", "in", "MSH2", "and", "MSH6", "in", "the", "MSI-L", "and", "MSI-H", "groups,", "respectively.", "Yearsley", "et", "al.", "[15],", "in", "their", "study", "of", "87", "patients", "with", "MSI", "colorectal", "cancers,", "found", "12", "patients", "(13.8%)", "with", "MLH1", "and", "MSH2", "germline", "mutations.", "Niessen", "et", "al.", "[16],", "however,", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "was", "82%", "in", "the", "young", "age", "group", "(", "<50", "years", "old", "<50", "years", "old", "),", "Niessen", "et", "al.", "[15]", "found", "that", "the", "rate", "of", "MSH2,", "MSH6", "and", "MLH1", "germline", "mutations", "in", "MSI", "carriers", "was", "82%.", "In", "our", "146", "patients", "with", "colorectal", "cancers,", "34", "patients", "(23.3%)", "had", "MSI", "colorectal", "cancer.", "This", "is", "comparable", "to", "the", "studies", "by", "Pinol", "et", "al.", "[13]", "and", "Yearsley", "et", "al.", "[16].", "Wong", "et", "al.", "[17]", "showed", "that", "in", "the", "case", "of", "sporadic", "endometrial", "carcinoma,", "MSI", "endometrial", "carcinoma", "accounted", "for", "26%", "of", "patients.", "Our", "results", "showed", "that", "there", "were", "15", "(10.3%)", "CRCs", "with", "MSI-L", "and", "19", "(13.0%)", "CRCs", "with", "MSL-H,", "respectively.", "Lamberti", "et", "al.", "[18]", "reported", "that", "MSI-L", "and", "MSI-H", "accounted", "for", "6%", "and", "17%,", "respectively,", "of", "German", "patients.", "These", "results", "are", "similar", "to", "ours.", "Unexpectedly,", "in", "the", "present", "study,", "the", "age", "of", "patients", "with", "MSS", "colorectal", "cancers", "(60", "yrs)", "was", "similar", "to", "the", "age", "of", "patients", "with", "MSI-H", "(61", "yrs).", "In", "contrast,", "the", "average", "age", "of", "patients", "with", "MSI-L", "colorectal", "cancer", "was", "71,", "which", "was", "quite", "different", "from", "the", "reports", "of", "other", "research", "groups", "[13,15,18].", "In", "a", "study", "of", "1263", "patients", "with", "colorectal", "cancers,", "Benatti", "et", "al.", "[19]", "found", "that", "those", "who", "were", "MSI", "carriers", "tended", "to", "have", "mucinous", "and", "right", "colonic", "tumours.", "Noda", "et", "al.", "[20]", "also", "found", "that", "MSI", " ", "carriers", "have", "more", "right", "colonic", "tumors.", "However,", "in", "our", "study,", "tumors", "in", "the", "MSI", "group", "were", "most", "commonly", "located", "at", "the", "rectum,", "and", "mucinous", "carcinoma", "was", "not", "the", "most", "common", "pathological", "type,", "as", "it", "only", "accounted", "for", "29%.", "Interestingly,", "patients", "in", "our", "MSI-L", "group", "were", "older", "than", "the", "MSS", "group.", "The", "reason", "for", "these", "findings", "is", "uncertain.", "Bettstetter", "et", "al.", "[20]", "reported", "that", "the", "average", "age", "of", "MSI", "CRCs", "with", "MLH1", "negative", "staining", "was", "80", "yrs,", "which", "was", "similar", "to", "our", "results.", "Most", "of", "these", "MSI", "CRCs", "were", "caused", "by", "MLH1", "promoter", "hypermethylation.", "In", "our", "group,", "out", "of", "34", "MSI", "CRCs,", "19", "CRCs", "(55.9%)", "were", "hypermethylated", "at", "the", "MLH1", "promoter,", "which", "accounted", "for", "73.7%", "of", "MSI-H", "CRCs", "and", "33.3%", "of", "MSI", "CRCs.", "Anacleto", "et", "al.", "[21]", "reported", "that", "8", "out", "of", "15", "MSI", "CRCs", "had", "MLH1", "promoter", "hypermethylation,", "which", "was", "similar", "to", "our", "results.", "Kim", "et", "al.", "[10]", "found", "that", "in", "MSI-H", "gastric", "cancers", ",", "the", "MLH1", "hypermethylation", "sporadic", " ", "colorectal", "cancer", "is", "the", "most", "important", "method", "to", "screen", "HNPCC.", "In", "2004,", "the", "NCI", "recommended", "the", "revised", "Bethesda", "criteria", "as", "a", "HNPCC", "screening", "guideline", "and", "established", "the", "HNPCC", "diagnostic", "procedures.", "These", "guidelines", "stated", "that", "MSI", "should", "firstly", "be", "identified", "in", "colorectal", "tumor", "tissue,", "and", "then", "genetic", "tests", "would", "be", "performed", "to", "confirm", "MMR", "gene", "germline", "mutations", "in", "a", "blood", "sample", "[6]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 25, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 9, 10, 0, 0, 0, 0, 0, 0, 0, 5, 6, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 11, 1, 2, 25, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 19, 0, 9, 0, 0, 0, 0, 0, 0, 0, 11, 12, 12, 12, 0, 19, 0, 9, 0, 0, 7, 8, 8, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 11, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 15, 16, 16, 15, 16, 16, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 19, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 7, 8, 17, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
At present, a number of publications have studied the value of the revised Bethesda criteria and the relevant diagnostic procedures [13,14]. However, there has not been any systematic report on germline mutations of MMR genes in the Chinese population. Moreover, we found that research from some countries have results that, if applied to the NCI recommendations, may have resulted in a missed HNPCC family or low pick-up rate of HNPCC. In a study by Pinol et al. from Spain [13], 287 out of 1222 patients (23.5%) complied with the revised Bethesda standard. Ninety-one patients (7.4%) were MSI carriers, but only 11 patients (0.9%) had germline mutations of MSH2 or MLH1. This means that among this group, only 0.9% of patients could be diagnosed as HNPCC. In a study by Yearsley et al. [14], out of 482 US patients with colorectal cancers, 87 patients (18%) were MSI carriers and only 12 cases (2.5%) had MMR gene germline mutations. These results may be explained by different case selections and sensitivity of the tests used. On the other hand, in their study of HNPCC related tumors in young patients (<50 years old), Niessen et al. [15] found that the rate of MSH2, MSH6 and MLH1 germline mutations in MSI carriers was 82%. In our 146 patients with colorectal cancers, 34 patients (23.3%) had MSI colorectal cancer. This is comparable to the studies by Pinol et al. [13] and Yearsley et al. [16]. Wong et al. [17] showed that in the case of sporadic endometrial carcinoma, MSI endometrial carcinoma accounted for 26% of patients. Our results showed that there were 15 (10.3%) CRCs with MSI-L and 19 (13.0%) CRCs with MSL-H, respectively. Lamberti et al. [18] reported that MSI-L and MSI-H accounted for 6% and 17%, respectively, of German patients. These results are similar to ours. Unexpectedly, in the present study, the age of patients with MSS colorectal cancers (60 yrs) was similar to the age of patients with MSI-H (61 yrs). In contrast, the average age of patients with MSI-L colorectal cancer was 71, which was quite different from the reports of other research groups [13,15,18]. In a study of 1263 patients with colorectal cancers, Benatti et al. [19] found that those who were MSI carriers tended to have mucinous and right colonic tumours. Noda et al. [20] also found that MSI carriers have more right colonic tumors. However, in our study, tumors in the MSI group were most commonly located at the rectum, and mucinous carcinoma was not the most common pathological type, as it only accounted for 29%. Interestingly, patients in our MSI-L group were older than the MSS group. The reason for these findings is uncertain. Bettstetter et al. [20] reported that the average age of MSI CRCs with MLH1 negative staining was 80 yrs, which was similar to our results. Most of these MSI CRCs were caused by MLH1 promoter hypermethylation. In our group, out of 34 MSI CRCs, 19 CRCs (55.9%) were hypermethylated at the MLH1 promoter, which accounted for 73.7% of MSI-H CRCs and 33.3% of MSI CRCs. Anacleto et al. [21] reported that 8 out of 15 MSI CRCs had MLH1 promoter hypermethylation, which was similar to our results. Kim et al. [10] found that in MSI-H gastric cancers, the MLH1 hypermethylation occurred in 89% of patients. Bettstetter et al. [20] showed that all sporadic MSI-H CRCs were hypermethylated at the MLH1 promoter. These results were similar to ours. Fourteen out of 16 MLH1 negatively staining CRCs were hypermethylated at the MLH1promoter. Mutation analysis revealed that 8 patients (23.5%) had MMR gene germline mutations out of 34 MSI patients. Five patients had MSH2 mutations and 3 had MSH6 mutations, while no population . Moreover, we found that research from some countries have results that, if applied to the NCI recommendations, may have resulted in a missed HNPCC family or low pick-up rate of HNPCC. In a study by Pinol et al. from Spain [13], 287 out of 1222 patients (23.5%) complied with the revised Bethesda standard. Ninety-one patients (7.4%) were MSI carriers, but only 11 patients (0.9%) had germline mutations of MSH2 or MLH1. This means that among this group, only 0.9% of patients could be diagnosed as HNPCC. In a study by Yearsley et al. [14], out of 482 US patients with colorectal cancers, 87 patients (18%) were MSI carriers and only 12 cases (2.5%) had MMR gene germline mutations. These results may be explained by different case selections and sensitivity of the tests used. On the other hand, in their study of HNPCC related tumors in young patients (<50 years old), Niessen et al. [15] found that the rate of MSH2, MSH6 and MLH1 germline mutations in MSI carriers was 82%. In our 146 patients with colorectal cancers, 34 patients (23.3%) had MSI colorectal cancer MSI carriers , but only 11 patients (0.9%) had germline mutations of MSH2 or MLH1. This means that among this group, only 0.9% of patients could be diagnosed as HNPCC. In a study by Yearsley et al. [14], out of 482 US patients with colorectal cancers, 87 patients (18%) were MSI carriers and only 12 cases (2.5%) had MMR gene germline mutations. These results may be explained by different case selections and sensitivity of the tests used. On the other hand, in their study of HNPCC related tumors in young patients (<50 years old), Niessen et al. [15] found that the rate of MSH2, MSH6 and MLH1 germline mutations in MSI carriers was 82%. In our 146 patients with colorectal cancers, 34 patients (23.3%) had MSI colorectal cancer. This is comparable to the studies by Pinol et al. [13] and Yearsley et al. [16]. Wong et al. [17] showed that in the case of sporadic endometrial carcinoma, MSI endometrial carcinoma accounted for 26% of patients. Our results showed that there were 15 (10.3%) CRCs with MSI-L and 19 (13.0%) CRCs with MSL-H, respectively. Lamberti et al. [18] reported that MSI-L and MSI-H accounted for 6% and 17%, respectively, of German patients. These results are similar to ours. Unexpectedly, in the present study, the age of patients with MSS colorectal cancers (60 yrs) was similar to the age of patients with MSI-H (61 yrs). In contrast, the average age of patients with MSI-L colorectal cancer was 71, which was quite different from the reports of other research groups [13,15,18]. In a study of 1263 patients with colorectal cancers, Benatti et al. [19] found that those who were MSI carriers tended to have mucinous and right colonic tumours. Noda et al. [20] also found that MSI carriers have more right colonic tumors. However, in our study, tumors in the MSI group were most commonly located at the rectum, and mucinous carcinoma was not the most common pathological type, as it only accounted for 29%. Interestingly, patients in our MSI-L group were older than the MSS group. The reason for these findings is uncertain. Bettstetter et al. [20] reported that the average age of MSI CRCs with MLH1 negative staining was 80 yrs, which was similar to our results. Most of these MSI CRCs were caused by MLH1 promoter hypermethylation. In our group, out of 34 MSI CRCs, 19 CRCs (55.9%) were hypermethylated at the MLH1 promoter, which accounted for 73.7% of MSI-H CRCs and 33.3% of MSI CRCs. Anacleto et al. [21] reported that 8 out of 15 MSI CRCs had MLH1 promoter hypermethylation, which was similar to our results. Kim et al. [10] found that in MSI-H gastric cancers, the MLH1 hypermethylation occurred in 89% of patients. Bettstetter et al. [20] showed that all sporadic MSI-H CRCs were hypermethylated at the MLH1 promoter. These results were similar to ours. Fourteen out of 16 MLH1 negatively staining CRCs were hypermethylated at the MLH1promoter. Mutation analysis revealed that 8 patients (23.5%) had MMR gene germline mutations out of 34 MSI patients. Five patients had MSH2 mutations and 3 had MSH6 mutations, while no MLH1 mutation was found. There were 2 and 6 patients who had mutations in MSH2 and MSH6 in the MSI-L and MSI-H groups, respectively. Yearsley et al. [15], in their study of 87 patients with MSI colorectal cancers, found 12 patients (13.8%) with MLH1 and MSH2 germline mutations. Niessen et al. [16], however, found that the rate of MSH2, MSH6 and MLH1 germline mutations was 82% 33.3% colorectal cancers US patients with colorectal cancers, 87 patients (18%) were MSI carriers and only 12 cases (2.5%) had MMR gene germline mutations. These results may be explained by different case selections and sensitivity of the tests used. On the other hand, in their study of HNPCC related tumors in young patients (<50 years old), Niessen et al. [15] found that the rate of MSH2, MSH6 and MLH1 germline mutations in MSI carriers was 82%. In our 146 patients with colorectal cancers, 34 patients (23.3%) had MSI colorectal cancer. This is comparable to the studies by Pinol et al. [13] and Yearsley et al. [16]. Wong et al. [17] showed that in the case of sporadic endometrial carcinoma, MSI endometrial carcinoma accounted for 26% of patients. Our results showed that there were 15 (10.3%) CRCs with MSI-L and 19 (13.0%) CRCs with MSL-H, respectively. Lamberti et al. [18] reported that MSI-L and MSI-H accounted for 6% and 17%, respectively, of German patients. These results are similar to ours. Unexpectedly, in the present study, the age of patients with MSS colorectal cancers (60 yrs) was similar to the age of patients with MSI-H (61 yrs). In contrast, the average age of patients with MSI-L colorectal cancer was 71, which was quite different from the reports of other research groups [13,15,18]. In a study of 1263 patients with colorectal cancers, Benatti et al. [19] found that those who were MSI carriers tended to have mucinous and right colonic tumours. Noda et al. [20] also found that MSI carriers have more right colonic tumors. However, in our study, tumors in the MSI group were most commonly located at the rectum, and mucinous carcinoma was not the most common pathological type, as it only accounted for 29%. Interestingly, patients in our MSI-L group were older than the MSS group. The reason for these findings is uncertain. Bettstetter et al. [20] reported that the average age of MSI CRCs with MLH1 negative staining was 80 yrs, which was similar to our results. Most of these MSI CRCs were caused by MLH1 promoter hypermethylation. In our group, out of 34 MSI CRCs, 19 CRCs (55.9%) were hypermethylated at the MLH1 promoter, which accounted for 73.7% of MSI-H CRCs and 33.3% of MSI CRCs . Anacleto et al. [21] reported that 8 out of 15 MSI CRCs had MLH1 promoter hypermethylation , which was similar to our results. Kim et al. [10] found that in MSI-H gastric cancers, the MLH1 hypermethylation occurred in 89% of patients. Bettstetter et al. [20] showed that all sporadic MSI-H CRCs were hypermethylated at the MLH1 promoter. These results were similar to ours. Fourteen out of 16 MLH1 negatively staining CRCs were hypermethylated at the MLH1promoter. Mutation analysis revealed that 8 patients (23.5%) had MMR gene germline mutations out of 34 MSI patients. Five patients had MSH2 mutations and 3 had MSH6 mutations, while no MLH1 mutation was found. There were 2 and 6 patients who had mutations in MSH2 and MSH6 in the MSI-L and MSI-H groups, respectively. Yearsley et al. [15], in their study of 87 patients with MSI colorectal cancers, found 12 patients (13.8%) with MLH1 and MSH2 germline mutations. Niessen et al. [16], however, found that the rate of MSH2, MSH6 and MLH1 germline mutations was 82% in the young age group (<50 years old). This was quite different from our group. This difference might be due to different case 87 patients (18%) were MSI carriers and only 12 cases (2.5%) had MMR gene germline mutations. These results may be explained by different case selections and sensitivity of the tests used. On the other hand, in their study of HNPCC related tumors in young patients (<50 years old), Niessen et al. [15] found that the rate of MSH2, MSH6 and MLH1 germline mutations in MSI carriers was 82%. In our 146 patients with colorectal cancers, 34 patients (23.3%) had MSI colorectal cancer. This is comparable to the studies by Pinol et al. [13] and Yearsley et al. [16]. Wong et al. [17] showed that in the case of sporadic endometrial carcinoma, MSI endometrial carcinoma accounted for 26% of patients. Our results showed that there were 15 (10.3%) CRCs with MSI-L and 19 (13.0%) CRCs with MSL-H, respectively. Lamberti et al. [18] reported that MSI-L and MSI-H accounted for 6% and 17%, respectively, of German patients. These results are similar to ours. Unexpectedly, in the present study, the age of patients with MSS colorectal cancers (60 yrs) was similar to the age of patients with MSI-H (61 yrs). In contrast, the average age of patients with MSI-L colorectal cancer was 71, which was quite different from the reports of other research groups [13,15,18]. In a study of 1263 patients with colorectal cancers, Benatti et al. [19] found that those who were MSI carriers tended to have mucinous and right colonic tumours. Noda et al. [20] also found that MSI carriers have more right colonic tumors. However, in our study, tumors in the MSI group were most commonly located at the rectum, and mucinous carcinoma was not the most common pathological type, as it only accounted for 29%. Interestingly, patients in our MSI-L group were older than the MSS group. The reason for these findings is uncertain. Bettstetter et al. [20] reported that the average age of MSI CRCs with MLH1 negative staining was 80 yrs, which was similar to our results. Most of these MSI CRCs were caused by MLH1 promoter hypermethylation. In our group, out of 34 MSI CRCs, 19 CRCs (55.9%) were hypermethylated at the MLH1 promoter, which accounted for 73.7% of MSI-H CRCs and 33.3% of MSI CRCs. Anacleto et al. [21] reported that 8 out of 15 MSI CRCs had MLH1 promoter hypermethylation, which was similar to our results. Kim et al. [10] found that in MSI-H gastric 2.5% ) had MMR gene germline mutations. These results may be explained by different case selections and sensitivity of the tests used. On the other hand, in their study of HNPCC related tumors in young patients (<50 years old), Niessen et al. [15] found that the rate of MSH2, MSH6 and MLH1 germline mutations in MSI carriers was 82%. In our 146 patients with colorectal cancers, 34 patients (23.3%) had MSI colorectal cancer. This is comparable to the studies by Pinol et al. [13] and Yearsley et al. [16]. Wong et al. [17] showed that in the case of sporadic endometrial carcinoma, MSI endometrial carcinoma accounted for 26% of patients. Our results showed that there were 15 (10.3%) CRCs with MSI-L and 19 (13.0%) CRCs with MSL-H, respectively. Lamberti et al. [18] reported that MSI-L and MSI-H accounted for 6% and 17%, respectively, of German patients. These results are similar to ours. Unexpectedly, in the present study, the age of patients with MSS colorectal cancers (60 yrs) was similar to the age of patients with MSI-H (61 yrs). In contrast, the average age of patients with MSI-L colorectal cancer was 71, which was quite different from the reports of other research groups [13,15,18]. In a study of 1263 patients with colorectal cancers, Benatti et al. [19] found that those who were MSI carriers tended to have mucinous and right colonic tumours. Noda et al. [20] also found that MSI carriers have more right colonic tumors. However, in our study, tumors in the MSI group were most commonly located at the rectum, and mucinous carcinoma was not the most common pathological type, as it only accounted for 29%. Interestingly, patients in our MSI-L group were older than the MSS group. The reason for these findings is uncertain. Bettstetter et al. [20] reported that the average age of MSI CRCs with MLH1 negative staining was 80 yrs, which was similar to our results. Most of these MSI CRCs were caused by MLH1 promoter hypermethylation. In our group, out of 34 cancers , 87 patients (18%) were MSI carriers and only 12 cases (2.5%) had MMR gene germline mutations. These results may be explained by different case selections and sensitivity of the tests used. On the other hand, in their study of HNPCC related tumors in young patients (<50 years old), Niessen et al. [15] found that the rate of MSH2, MSH6 and MLH1 germline mutations in MSI carriers was 82%. In our 146 patients with colorectal cancers, 34 patients (23.3%) had MSI colorectal cancer. This is comparable to the studies by Pinol et al. [13] and Yearsley et al. [16]. Wong et al. [17] showed that in the case of sporadic endometrial carcinoma, MSI endometrial carcinoma accounted for 26% of patients. Our results showed that there were 15 (10.3%) CRCs with MSI-L and 19 (13.0%) CRCs with MSL-H, respectively. Lamberti et al. [18] reported that MSI-L and MSI-H accounted for 6% and 17%, respectively, of German patients. These results are similar to ours. Unexpectedly, in the present study, the age of patients with MSS colorectal cancers (60 yrs) was similar to the age of patients with MSI-H (61 yrs). In contrast, the average age of patients with MSI-L colorectal cancer was 71, which was quite different from the reports of other research groups [13,15,18]. In a study of 1263 patients with colorectal cancers, Benatti et al. [19] found that those who were MSI carriers tended to have mucinous and right colonic tumours. Noda et al. [20] also found that MSI carriers have more right colonic tumors. However, in our study, tumors in the MSI group were most commonly located at the rectum, and mucinous carcinoma was not the most common pathological type, as it only accounted for 29%. Interestingly, patients in our MSI-L group were older than the MSS group. The reason for these findings is uncertain. Bettstetter et al. [20] reported that the average age of MSI CRCs with MLH1 negative staining was 80 yrs, which was similar to our results. Most of these MSI CRCs were caused by MLH1 promoter hypermethylation. In our group, out of 34 MSI CRCs, 19 CRCs (55.9%) were hypermethylated at the MLH1 promoter, which accounted for 73.7% of MSI-H CRCs and 33.3% of MSI CRCs. Anacleto et al. [21] reported that 8 out of 15 MSI CRCs had MLH1 promoter hypermethylation, which was similar to our results. Kim et al. [10] found that in MSI-H gastric cancers, the MLH1 hypermethylation occurred in 89% of patients. Bettstetter et al. [20] showed that all sporadic MSI-H CRCs were hypermethylated at the MLH1 promoter. These results were similar to ours. Fourteen out of 16 MLH1 negatively staining CRCs were hypermethylated at the MLH1promoter. Mutation analysis revealed that 8 patients (23.5%) had MMR gene germline mutations out of 34 MSI patients. Five patients had MSH2 mutations and 3 had MSH6 mutations, while no MLH1 mutation was found. There were 2 and 6 patients who had mutations in MSH2 and MSH6 in the MSI-L and MSI-H groups, respectively. Yearsley et al. [15], in their study of 87 patients with MSI colorectal cancers, found 12 patients (13.8%) with MLH1 and MSH2 germline mutations. Niessen et al. [16], however, found that the rate of MSH2, MSH6 and MLH1 germline mutations was 82% in the young age group (<50 years old). This was quite different from our group. This difference might be due to different case selections of the two groups. Our study was more representative of the patient population because it was a successive cohort study. Most importantly, the above differences may also be explained by underlying differences in genetic background between Chinese and Western populations 0.9% 23.5% ) complied with the revised Bethesda standard. Ninety-one patients (7.4%) were MSI carriers, but only 11 patients (0.9%) had germline mutations of MSH2 or MLH1. This means that among this group, only 0.9% of patients could be diagnosed as HNPCC. In a study by Yearsley et al. [14], out of 482 US patients with colorectal cancers, 87 patients (18%) were MSI carriers and only 12 cases (2.5%) had MMR gene germline mutations. These results may be explained by different case selections and sensitivity of the tests used. On the other hand, in their study of HNPCC related tumors in young patients (<50 years old), Niessen et al. [15] found that the rate of MSH2, MSH6 and MLH1 germline mutations in MSI carriers was 82%. In our 146 patients with colorectal cancers, 34 patients (23.3%) had MSI colorectal cancer. This is comparable to the studies by Pinol et al. [13] and Yearsley et al. [16]. Wong et al. [17] showed that in the case of sporadic endometrial carcinoma, MSI endometrial carcinoma accounted for 26% of patients. Our results showed that there were 15 (10.3%) CRCs with MSI-L and 19 (13.0%) CRCs with MSL-H, respectively. Lamberti et al. [18] reported that MSI-L and MSI-H accounted for 6% and 17%, respectively, of German patients. These results are similar to ours. Unexpectedly, in the present study, the age of patients with MSS colorectal cancers (60 yrs) was similar to the age of patients with MSI-H (61 yrs). In contrast, the average age of patients with MSI-L colorectal cancer was 71, which was quite different from the reports of other research groups [13,15,18]. In a study of 1263 patients with colorectal cancers, Benatti et al. [19] found that those who were MSI carriers tended to have mucinous and right colonic tumours. Noda et al. [20] also found that MSI carriers have more right colonic tumors. However, in our study, tumors in the MSI group were most commonly located at the rectum, and mucinous carcinoma was not the most common pathological type, as it only accounted for 29%. Interestingly, patients in our MSI-L group were older than the MSS group. The reason for these findings is uncertain. Bettstetter et al. [20] reported that the average age of MSI CRCs with MLH1 negative staining was 80 yrs, which was similar to our results. Most of these MSI CRCs were caused by MLH1 promoter hypermethylation. In our group, out of 34 MSI CRCs, 19 CRCs (55.9%) were hypermethylated at the MLH1 promoter, which accounted for 73.7% of MSI-H CRCs and 33.3% of MSI CRCs. Anacleto et al. [21] reported that 8 out of 15 MSI CRCs had MLH1 promoter hypermethylation, which was similar to our results. Kim et al. [10] found that in MSI-H gastric cancers, the MLH1 hypermethylation occurred in 89% of patients. Bettstetter et al. [20] showed that all sporadic MSI-H CRCs were hypermethylated at the MLH1 promoter. These results were similar to ours. Fourteen out of 16 MLH1 negatively staining CRCs were hypermethylated at the MLH1promoter. Mutation analysis revealed that 8 patients (23.5%) had MMR gene germline mutations out of 34 MSI patients. Five patients had MSH2 mutations and 3 had MSH6 mutations, while no MLH1 mutation was found. There were 2 and 6 patients who had mutations in MSH2 and MSH6 in the MSI-L and MSI-H groups, respectively. Yearsley et al. [15], in their study of 87 patients with MSI colorectal cancers, found 12 patients (13.8%) with MLH1 and MSH2 germline mutations. Niessen et al. [16], however, found that the rate of MSH2, MSH6 and MLH1 germline mutations was 82% in the young age group ( <50 years old <50 years old ), Niessen et al. [15] found that the rate of MSH2, MSH6 and MLH1 germline mutations in MSI carriers was 82%. In our 146 patients with colorectal cancers, 34 patients (23.3%) had MSI colorectal cancer. This is comparable to the studies by Pinol et al. [13] and Yearsley et al. [16]. Wong et al. [17] showed that in the case of sporadic endometrial carcinoma, MSI endometrial carcinoma accounted for 26% of patients. Our results showed that there were 15 (10.3%) CRCs with MSI-L and 19 (13.0%) CRCs with MSL-H, respectively. Lamberti et al. [18] reported that MSI-L and MSI-H accounted for 6% and 17%, respectively, of German patients. These results are similar to ours. Unexpectedly, in the present study, the age of patients with MSS colorectal cancers (60 yrs) was similar to the age of patients with MSI-H (61 yrs). In contrast, the average age of patients with MSI-L colorectal cancer was 71, which was quite different from the reports of other research groups [13,15,18]. In a study of 1263 patients with colorectal cancers, Benatti et al. [19] found that those who were MSI carriers tended to have mucinous and right colonic tumours. Noda et al. [20] also found that MSI carriers have more right colonic tumors. However, in our study, tumors in the MSI group were most commonly located at the rectum, and mucinous carcinoma was not the most common pathological type, as it only accounted for 29%. Interestingly, patients in our MSI-L group were older than the MSS group. The reason for these findings is uncertain. Bettstetter et al. [20] reported that the average age of MSI CRCs with MLH1 negative staining was 80 yrs, which was similar to our results. Most of these MSI CRCs were caused by MLH1 promoter hypermethylation. In our group, out of 34 MSI CRCs, 19 CRCs (55.9%) were hypermethylated at the MLH1 promoter, which accounted for 73.7% of MSI-H CRCs and 33.3% of MSI CRCs. Anacleto et al. [21] reported that 8 out of 15 MSI CRCs had MLH1 promoter hypermethylation, which was similar to our results. Kim et al. [10] found that in MSI-H gastric cancers , the MLH1 hypermethylation sporadic colorectal cancer is the most important method to screen HNPCC. In 2004, the NCI recommended the revised Bethesda criteria as a HNPCC screening guideline and established the HNPCC diagnostic procedures. These guidelines stated that MSI should firstly be identified in colorectal tumor tissue, and then genetic tests would be performed to confirm MMR gene germline mutations in a blood sample [6].
3034663-02-Background-p01
[ "The", "majority", "of", "UVs", "are", "missense", "mutations", "or", "small", "in-frame", "deletions.", "The", "human", "gene", "pool", "harbours", "a", "vast", "number", "of", "rare", "missense", "substitutions,", "70%", "of", "which", "are", "at", "least", "mildly", "deleterious", "[2].", "Integration", "of", "various", "lines", "of", "evidence", "may", "help", "to", "classify", "UVs.", "Information", "on:", "1)", "frequencies", "in", "cases", "cases", " ", "in", "which", "a", "causative", "mutation", "is", "identified", "is", "far", "from", "ideal.", "All", "members", "from", "a", "family", "with", "a", "strong", "history", "of", "cancer", "and", "no", "causative", "mutation", "detected", "are", "included", "in", "a", "surveillance", "program.", "Identification", "of", "mutations", "depends", "on", "the", "specific", "syndrome", "and", "the", "criteria", "applied", "to", "select", "patients", "for", "genetic", "analyses." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The majority of UVs are missense mutations or small in-frame deletions. The human gene pool harbours a vast number of rare missense substitutions, 70% of which are at least mildly deleterious [2]. Integration of various lines of evidence may help to classify UVs. Information on: 1) frequencies in cases cases in which a causative mutation is identified is far from ideal. All members from a family with a strong history of cancer and no causative mutation detected are included in a surveillance program. Identification of mutations depends on the specific syndrome and the criteria applied to select patients for genetic analyses.
1601966-05-Conclusion-p01
[ "Chromosomal", "regions", "that", "are", "frequently", "deleted", "in", "CRC", "very", "often", "comprise", "islands", "in", "which", "we", "found", "reduced", "expression.", "Although", "many", "regions", "that", "are", "known", "to", "be", "amplified", "in", "colorectal", " ", "tumors", "show", "a", "gain", "of", "expression,", "there", "are", "also", "a", "considerable", "number", "of", "amplified", "islands", "that", "show", "no", "alterations", "or", "even", "down-regulation.", "Comparison", "of", "published", "CGH", "studies", "with", "our", "expression", "data", "suggests", "that", "amplified", "or", "deleted", "chromosomal", "regions", "are", "responsible", "for", "many", "islands", "with", "aberrant", "expression.", "However,", "we", "suggest", "that", "it", "is", "necessary", "to", "invoke", "other", "mechanism", "like", "epigenetic", "regulation", "of", "chromatin", "or", "disruption", "of", "enhancer", "actions", "to", "explain", "the", "remaining", "expression", "imbalances." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Chromosomal regions that are frequently deleted in CRC very often comprise islands in which we found reduced expression. Although many regions that are known to be amplified in colorectal tumors show a gain of expression, there are also a considerable number of amplified islands that show no alterations or even down-regulation. Comparison of published CGH studies with our expression data suggests that amplified or deleted chromosomal regions are responsible for many islands with aberrant expression. However, we suggest that it is necessary to invoke other mechanism like epigenetic regulation of chromatin or disruption of enhancer actions to explain the remaining expression imbalances.
3034663-03-Methods-p02
[ "A", "subset", "of", "colorectal", "tumour", "DNA", "samples", "from", "17", "patients", "carrying", "the", "p.Lys618Ala", "variant", "(eight", "from", "the", "familial", "group", "and", "nine", "from", "the", "sporadic", "CRC", "group)", "was", "screened", "for", "MSI", "status", "using", "five", "mononucleotide", "markers", "(BAT26,", "BAT25,", "NR21,", "NR24", "and", "NR27)", "and", "multiplex", "PCR", "as", "previously", "described", "by", "Buhard", "et", "al", "[8]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
A subset of colorectal tumour DNA samples from 17 patients carrying the p.Lys618Ala variant (eight from the familial group and nine from the sporadic CRC group) was screened for MSI status using five mononucleotide markers (BAT26, BAT25, NR21, NR24 and NR27) and multiplex PCR as previously described by Buhard et al [8].
1334229-03-Methods-p01
[ "Incident", "cancer", "cases", "are", "identified", "by", "monitoring", "of", "the", "entire", "cohort", "for", "cancer", "occurrence", "through", "annual", "record", "linkage", "to", "the", "Netherlands", "Cancer", "Registry,", "i.e.", "nine", "regional", "cancer", "registries", "throughout", "the", "Netherlands,", "and", "to", "PALGA,", "a", "nationwide", "network", "and", "registry", "of", "histo-", "and", "cytopathology", "[30].", "Together,", "the", "NCR", "and", "PALGA", "provide", "a", "near", "100%", "coverage", "of", "the", "municipalities", "included", "in", "the", "NLCS.", "The", "first", "2.3", "years", "of", "follow", "up", "were", "excluded", "because", "of", "possible", "pre-clinical", "disease", "affecting", "exposure", "status", "and", "because", "of", "incomplete", "nationwide", "coverage", "of", "PALGA", "in", "some", "of", "the", "municipalities", "included", "in", "the", "NLCS", "in", "that", "period.", "From", "1989", "until", "1994,", "929", "incident", "cases", "with", "histologically", "confirmed", "colorectal", "cancer", "were", "identified", "within", "the", "cohort,", "of", "whom", "819", "could", "also", "be", "linked", "to", "a", "PALGA", "report", "of", "the", "lesion." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Incident cancer cases are identified by monitoring of the entire cohort for cancer occurrence through annual record linkage to the Netherlands Cancer Registry, i.e. nine regional cancer registries throughout the Netherlands, and to PALGA, a nationwide network and registry of histo- and cytopathology [30]. Together, the NCR and PALGA provide a near 100% coverage of the municipalities included in the NLCS. The first 2.3 years of follow up were excluded because of possible pre-clinical disease affecting exposure status and because of incomplete nationwide coverage of PALGA in some of the municipalities included in the NLCS in that period. From 1989 until 1994, 929 incident cases with histologically confirmed colorectal cancer were identified within the cohort, of whom 819 could also be linked to a PALGA report of the lesion.
1619718-04-Results-p02
[ "With", "respect", "to", "the", "25", "serrated", "polyps", "five", " ", "Group", "B", "polyps", "with", "KRAS", "mutation,", "the", "adenomatous", "component", "showed", "both", "villous", "change", "and", "serration." ]
[ 0, 0, 0, 0, 0, 0, 1, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
With respect to the 25 serrated polyps five Group B polyps with KRAS mutation, the adenomatous component showed both villous change and serration.
1619718-05-Discussion-p04
[ "KRAS", "mutation", "has", "been", "linked", "to", "the", "initiation", "of", "hyperplastic", "aberrant", "crypt", "foci", "and", "small", "HPs7,38,55", "and", "is", "therefore", "closely", "associated", "with", "the", "development", "of", "glandular", "serration.", "While", "the", "acquisition", "of", "KRAS", "mutation", "is", "also", "observed", "in", "adenomas,", "this", "change", "is", "correlated", "with", "the", "development", "of", "a", "villous", "architecture", "and", "in", "some", "cases", "the", "presence", "of", "epithelial", "serration", "(see", "Discussion", "of", "Group", "B", "serrated", "polyps", "above).", "It", "may", "therefore", "be", "conceptually", "correct", "to", "view", "KRAS", "mutation", "as", "adding", "a", "serrated", "molecular", "signature", "to", "the", "traditional", "adenoma", "and", "hence", "providing", "an", "additional", "‘fusion’", "pathway.", "However,", "a", "mechanistic", "link", "between", "KRAS", "mutation", "and", "the", "morphogenesis", "of", "serration", "and", "villous", "change", "remains", "to", "be", "established.", "MGMT", "is", "again", "implicated", "in", "this", "second", "type", "of", "‘fusion’", "since", "methylation", "and", "inactivation", "of", "this", "DNA", "repair", "gene", "has", "been", "linked", "to", "G:C", "to", "A:T", "transitions", "in", "KRAS.56–58", "In", "this", "study", "there", "was", "an", "association", "between", "loss", "of", "expression", "of", "MGMT", "aberrant", "nuclear", "expression", "of", "p53", " ", "in", "three", "serrated", "polyps", "with", "dysplasia", "(Figure", "2),", "but", "not", "in", "the", "single", "DNA", "microsatellite", "stable", "status", " ", "(a", "‘fusion’", "pathway", "shown", "in", "Table", "3).49,50" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 7, 8, 8, 8, 8, 7, 8, 8, 8, 8, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 19, 20, 20, 20, 0, 0, 0, 0, 0, 0, 0, 0 ]
KRAS mutation has been linked to the initiation of hyperplastic aberrant crypt foci and small HPs7,38,55 and is therefore closely associated with the development of glandular serration. While the acquisition of KRAS mutation is also observed in adenomas, this change is correlated with the development of a villous architecture and in some cases the presence of epithelial serration (see Discussion of Group B serrated polyps above). It may therefore be conceptually correct to view KRAS mutation as adding a serrated molecular signature to the traditional adenoma and hence providing an additional ‘fusion’ pathway. However, a mechanistic link between KRAS mutation and the morphogenesis of serration and villous change remains to be established. MGMT is again implicated in this second type of ‘fusion’ since methylation and inactivation of this DNA repair gene has been linked to G:C to A:T transitions in KRAS.56–58 In this study there was an association between loss of expression of MGMT aberrant nuclear expression of p53 in three serrated polyps with dysplasia (Figure 2), but not in the single DNA microsatellite stable status (a ‘fusion’ pathway shown in Table 3).49,50
1619718-01-Abstract-p01
[ "Aim" ]
[ 0 ]
Aim
1619718-04-Results-p01
[ "SSAs", "were", "more", "likely", "to", "have", "BRAF", "mutation", "(81%)", "than", "either", "SAs", "(33%)", "(P", "<", "0.001)", "or", "MPs", "(40%)", "(P", "<", "0.02).", "KRAS", "mutation", "was", "infrequent", "among", "both", "SSAs", "(3%)", "and", "HPs", "(", "4%", "V600E", " ", "could", "be", "assessed", "in", "all", "polyps", "except", "for", "a", "single", "TA", "<", " ", "10", "mm.", "BRAF", "mutation", "was", "found", "in", "82", "of", "189", "polyps", "(43%).", "BRAF", "and", "KRAS", "mutations", "were", "negatively", "correlated,", "with", "only", "four", "polyps", " ", "having", "both", "mutations", "(two", "TAs,", "one", "TVA", "and", "one", "SSA).", "The", "three", "conventional", "adenomas", "with", "mutations", "of", "both", "BRAF", "and", "KRAS", "were", "among", "only", "four", "adenomas", "that", "had", "any", "BRAF", "mutations", "at", "all.", "Mutation", "frequencies", "for", "both", "KRAS", "and", "BRAF", "were", "distributed", "differently", "across", "the", "seven", "polyp", "groups", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
SSAs were more likely to have BRAF mutation (81%) than either SAs (33%) (P < 0.001) or MPs (40%) (P < 0.02). KRAS mutation was infrequent among both SSAs (3%) and HPs ( 4% V600E could be assessed in all polyps except for a single TA <   10 mm. BRAF mutation was found in 82 of 189 polyps (43%). BRAF and KRAS mutations were negatively correlated, with only four polyps having both mutations (two TAs, one TVA and one SSA). The three conventional adenomas with mutations of both BRAF and KRAS were among only four adenomas that had any BRAF mutations at all. Mutation frequencies for both KRAS and BRAF were distributed differently across the seven polyp groups (Table 1).
1619718-01-Abstract-p01
[ "Conclusions" ]
[ 0 ]
Conclusions
3034663-03-Methods-p01
[ "DNA", "from", "blood", "cells", "(familial", "cancer", "cases", "and", "controls)", "or", "colorectal", "mucosa", "of", "normal", "appearance", "(sporadic", "cases)", "was", "used", "for", "the", "c.1852_1853AA>GC", "variant", "genotyping.", "This", "was", "assessed", "using", "the", "iPLEX", "Gold", "method", "(Sequenom,", "CA,", "USA),", "in", "which", "single-base", "extension", "and", "MALDI-TOF", "technology", "are", "employed", "for", "allelic", "discrimination.", "These", "experiments", "were", "carried", "out", "at", "the", "Centro", "Español", "de", "Genotipado", "(CEGEN)", "genotyping", "platform", "facilities.", "Quality", "control", "for", "genotyping", "was", "conducted", "by", "direct", "sequencing", "of", "familial", "cancer", "subjects", "who", "underwent", "genetic", "analysis", "for", "MLH1", "MSH6", "CRC", " ", "patients." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 1, 0, 0 ]
DNA from blood cells (familial cancer cases and controls) or colorectal mucosa of normal appearance (sporadic cases) was used for the c.1852_1853AA>GC variant genotyping. This was assessed using the iPLEX Gold method (Sequenom, CA, USA), in which single-base extension and MALDI-TOF technology are employed for allelic discrimination. These experiments were carried out at the Centro Español de Genotipado (CEGEN) genotyping platform facilities. Quality control for genotyping was conducted by direct sequencing of familial cancer subjects who underwent genetic analysis for MLH1 MSH6 CRC patients.
3034663-03-Methods-p01
[ "Three", "characterized", "LS", "families", "that", "fulfilled", "the", "Amsterdam", "II", "Criteria", "and", "that", "consisted", "of", "members", "with", "the", "p.Lys618Ala", "variant", "were", "included", "to", "assess", "co-occurrence", "and", "co-segregation.", "Two", " ", "families", "attended", "the", "Genetic", "Counselling", "in", "Cancer", "Units", "of", "the", "Elche", "and", "La", "Fe", "Hospitals", "and", "one", "family", "was", "a", "member", "of", "the", "EPICOLON", "cohort", "[7]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Three characterized LS families that fulfilled the Amsterdam II Criteria and that consisted of members with the p.Lys618Ala variant were included to assess co-occurrence and co-segregation. Two families attended the Genetic Counselling in Cancer Units of the Elche and La Fe Hospitals and one family was a member of the EPICOLON cohort [7].
1619718-04-Results-p01
[ "Mutation", "frequencies", "for", "both", "KRAS", "(P", "<", "0.0001)", "and", "BRAF", "(P", "<", "0.0001)", "are", "distributed", "differently", "across", "the", "seven", "classes", "of", "polyp", "(see", "Results", "for", "individual", "comparisons).", "Distribution", "of", "MGMT", "loss", "differs", "across", "the", "seven", "classes", "of", "polyp", "(P", "<", "0.001)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutation frequencies for both KRAS (P < 0.0001) and BRAF (P < 0.0001) are distributed differently across the seven classes of polyp (see Results for individual comparisons). Distribution of MGMT loss differs across the seven classes of polyp (P < 0.001).
1557864-01-Abstract-p01
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
2386495-03-Methods-p01
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
2275286-01-Abstract-p01
[ "Thirty-four", "out", "of", "the", "146", "colorectal", "cancers", "(CRCs,", "23.2%)", "were", "MSI,", "including", "19", "MSI-H", "CRCs", "and", "15", "MSI-L", "CRCS.", "Negative", "staining", "for", "MSH2", "was", "found", "in", "8", "CRCs,", "negative", "staining", "for", "MSH6", "was", "found", "in", "6", "CRCs.", "One", "MSI-H", "CRC", "was", "negative", "for", "both", "MSH6", "and", "MSH2.", "Seventeen", "CRCs", "stained", "negatively", "for", "MLH1.", "MLH1", "promoter", "methylation", "was", "determined", "in", "34", "MSI", "CRCs.", "Hypermethylation", "of", "the", "MLH1", "promoter", "occurred", "in", "14", "(73.7%)", "out", "of", "19", "colorectal", " ", "cancer", "(HNPCC)", "is", "an", "autosomal", "dominant", "syndrome.", "The", "National", "Cancer", "Institute", "(NCI)", "has", "recommended", "the", "Revised", "Bethesda", "guidelines", "for", "screening", "HNPCC.", "There", "has", "been", "a", "great", "deal", "of", "research", "on", "the", "value", "of", "these", "tests", "in", "other", "countries.", "However,", "literature", "about", "the", "Chinese", "population", "is", "scarce.", "Our", "objective", "is", "to", "detect", "and", "study", "microsatellite", "instability", "(MSI)", "and", "mismatch", "repair", "(MMR)", "gene", "germline", "mutation", "carriers", "among", "a", "Chinese", "population", "with", "colorectal", "cancer." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 12, 12, 12, 12, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Thirty-four out of the 146 colorectal cancers (CRCs, 23.2%) were MSI, including 19 MSI-H CRCs and 15 MSI-L CRCS. Negative staining for MSH2 was found in 8 CRCs, negative staining for MSH6 was found in 6 CRCs. One MSI-H CRC was negative for both MSH6 and MSH2. Seventeen CRCs stained negatively for MLH1. MLH1 promoter methylation was determined in 34 MSI CRCs. Hypermethylation of the MLH1 promoter occurred in 14 (73.7%) out of 19 colorectal cancer (HNPCC) is an autosomal dominant syndrome. The National Cancer Institute (NCI) has recommended the Revised Bethesda guidelines for screening HNPCC. There has been a great deal of research on the value of these tests in other countries. However, literature about the Chinese population is scarce. Our objective is to detect and study microsatellite instability (MSI) and mismatch repair (MMR) gene germline mutation carriers among a Chinese population with colorectal cancer.
1619718-04-Results-p01
[ "KRAS", "mutation", "occurred", "in", "26.5%", "and", "BRAF", "mutation", "in", "4.8%", "of", "adenomas", "(all", "types)", "(Table", "1)", "(P", "<", "0.0001).", "TVAs/VAs", "were", "more", "likely", "to", "have", "KRAS", "mutation", "TA", " ", "<", " ", "10", "mm.", "Overall,", "34", "of", "188", "polyps", "(18%)", "had", "mutation", "of", "KRAS.", "Twenty-eight", "mutations", "were", "in", "codon", "12", "(20", "G→A,", "seven", "G→T", "and", "one", "G→C)", "and", "six", "mutations", "were", "in", "codon", "13", "(all", "G→A).", "One", "serrated", "adenoma", "had", "two", "KRAS", "mutations", "in", "codon", "12", "(G→T", "at", "position", "35", "and", "T→G", "at", "position", "36).", "BRAF", "mutation", "at", "V600E", "could", "be", "assessed", "in", "all", "polyps", "except", "for", "a", "single", "TA", "<", " ", "10", "mm.", "BRAF", "mutation", "was", "found", "in", "82", "of", "189", "polyps", "(43%).", "BRAF", "and", "KRAS", "mutations", "were", "negatively", "correlated,", "with", "only", "four", "polyps", "having", "both", "mutations", "(two", "TAs,", "one", "TVA", "and", "one", "SSA).", "The", "three", "conventional", "adenomas", "with", "mutations", "of", "both", "BRAF", "and", "KRAS", "were", "among", "only", "four", "adenomas", "that", "had", "any", "BRAF", "mutations", "at", "all.", "Mutation", "frequencies", "for", "both", "KRAS", "and", "BRAF", "were", "distributed", "differently", "across", "the", "seven", "polyp", "groups", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
KRAS mutation occurred in 26.5% and BRAF mutation in 4.8% of adenomas (all types) (Table 1) (P < 0.0001). TVAs/VAs were more likely to have KRAS mutation TA <   10 mm. Overall, 34 of 188 polyps (18%) had mutation of KRAS. Twenty-eight mutations were in codon 12 (20 G→A, seven G→T and one G→C) and six mutations were in codon 13 (all G→A). One serrated adenoma had two KRAS mutations in codon 12 (G→T at position 35 and T→G at position 36). BRAF mutation at V600E could be assessed in all polyps except for a single TA <   10 mm. BRAF mutation was found in 82 of 189 polyps (43%). BRAF and KRAS mutations were negatively correlated, with only four polyps having both mutations (two TAs, one TVA and one SSA). The three conventional adenomas with mutations of both BRAF and KRAS were among only four adenomas that had any BRAF mutations at all. Mutation frequencies for both KRAS and BRAF were distributed differently across the seven polyp groups (Table 1).
1619718-05-Discussion-p02
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1601966-02-Background-p01
[ "Background" ]
[ 0 ]
Background
1601966-03-Results-p12
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
2275286-01-Abstract-p01
[ "In", "146", "prospectively", "recruited", "consecutive", "patients", "with", "clinically", "proven", "colorectal", "cancer,", "MSI", "carriers", "were", "identified", "by", "analysis", "of", "tumor", "tissue", "using", "multiplex", "fluorescence", "polymerase", "chain", "reaction", "(PCR)", "using", "the", "NCI", "recommended", "panel", "and", "classified", "into", "microsatellite", "instability-low", "(MSI-L),", "microsatellite", "instability-high", "(MSI-H)", "and", "microsatellite", "stable", "(MSS)", "groups.", "Immunohistochemical", "staining", "for", "MSH2,", "MSH6", "and", "MLH1", "on", "tissue", "microarrays", "(TMAs)", "was", "performed,", "and", "methylation", "of", "the", "MLH1", "promoter", "was", "analyzed", "by", "quantitative", "methylation", "specific", "PCR", "(MSP).", "Germline", "mutation", "analysis", "of", "blood", "samples", "was", "performed", "for", "MSH2,", "MSH6", "and", "MLH1", "genes." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In 146 prospectively recruited consecutive patients with clinically proven colorectal cancer, MSI carriers were identified by analysis of tumor tissue using multiplex fluorescence polymerase chain reaction (PCR) using the NCI recommended panel and classified into microsatellite instability-low (MSI-L), microsatellite instability-high (MSI-H) and microsatellite stable (MSS) groups. Immunohistochemical staining for MSH2, MSH6 and MLH1 on tissue microarrays (TMAs) was performed, and methylation of the MLH1 promoter was analyzed by quantitative methylation specific PCR (MSP). Germline mutation analysis of blood samples was performed for MSH2, MSH6 and MLH1 genes.
3034663-03-Methods-p01
[ "Families", "carrying", "the", "p.Lys618Ala", "variant" ]
[ 0, 0, 0, 0, 0 ]
Families carrying the p.Lys618Ala variant
1601966-03-Results-p05
[ "We", "observed", "increased", "expression", "of", "genes", "in", "chromosomal", "region", "12q14.2-12q22", "(see", "Figures", "15,", "16,", "17).", "The", "MDM2", "gene", "at", "12q15", "is", "a", "possible", "target", "of", "this", "misregulation.", "However,", "within", "this", "large", "region", "there", "is", "a", "smaller", "region", "at", "12q21.1-q21.2", "spanning", "eight", "genes", "that", "exhibit", "exceptionally", "high", "expression", "in", "our", "tumor", "samples.", "Among", "these", "is", "LGR5", "alias", "GPR49,", "a", "G-protein", "coupled", "receptor", "that", "has", "large", "leucine-rich", "repeats", "in", "its", "N-terminus.", "We", "could", "confirm", "the", "up-regulation", "of", "GPR49", "NDRGL3", ",", "RPN2", "and", "CTNNBL1.", "Also", "note", "the", "gene", "C20orf110", "alias", "T", "P53I", "ITCH", ",", "DNCL2A,", "ITG4BP,", "C20orf24,", "NDRGL3,", "RPN2", "and", "CTNNBL1.", "Also", "note", "the", "gene", "C20orf110", "alias", "TP53INP2", "which", "is", "down-regulated", "in", "the", "majority", "of", "tumors." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 5, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
We observed increased expression of genes in chromosomal region 12q14.2-12q22 (see Figures 15, 16, 17). The MDM2 gene at 12q15 is a possible target of this misregulation. However, within this large region there is a smaller region at 12q21.1-q21.2 spanning eight genes that exhibit exceptionally high expression in our tumor samples. Among these is LGR5 alias GPR49, a G-protein coupled receptor that has large leucine-rich repeats in its N-terminus. We could confirm the up-regulation of GPR49 NDRGL3 , RPN2 and CTNNBL1. Also note the gene C20orf110 alias T P53I ITCH , DNCL2A, ITG4BP, C20orf24, NDRGL3, RPN2 and CTNNBL1. Also note the gene C20orf110 alias TP53INP2 which is down-regulated in the majority of tumors.
1601966-03-Results-p05
[ "Up-regulation", "of", "mRNA", "expression", "in", "human", "chromosomal", "region", "20q11.22-q11.23", "(patient", "counts", "with", "coordinate", "up-regulation).", "Grayscale", "plot", "of", "cross-comparison", "of", "up-regulation", "patterns", "across", "patients", "for", "gene", "pairs", "in", "a", "particular", "region.", "Both,", "horizontal", "and", "vertical", "axes", "comprise", "the", "same", "genes", "in", "chromosomal", "order.", "In", "each", "square", "total", "counts", "of", "patients", "with", "consistent", "up-regulation", "in", "two", "genes", "are", "coded", "by", "different", "shades", "of", "gray.", "Dark", "squared", "regions", "along", "the", "diagonal", "indicate", "coordinated", "regulation", "in", "patient", "subgroups.", "Note,", "that", "many", "more", "patients", "show", "up-regulation", "as", "indicated", "by", "dark", "spots", "in", "this", "plot", "than", "down-regulation", "as", "indicated", "by", "dark", "spots", "in", "Figure", "14.", "The", "known", "most", "frequently", "up-regulated", "genes", "in", "this", "region", "are", "EIF2S2,", "AHCY,", "ITCH,", "DNCL2A,", "ITG4BP,", "C20orf24,", "NDRGL3,", "RPN2", "and", "CTNNBL1.", "Also", "note", "the", "gene", "C20orf110", "alias", "TP53INP2", "which", "is", "down-regulated", "in", "the", "majority", "of", "tumors." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Up-regulation of mRNA expression in human chromosomal region 20q11.22-q11.23 (patient counts with coordinate up-regulation). Grayscale plot of cross-comparison of up-regulation patterns across patients for gene pairs in a particular region. Both, horizontal and vertical axes comprise the same genes in chromosomal order. In each square total counts of patients with consistent up-regulation in two genes are coded by different shades of gray. Dark squared regions along the diagonal indicate coordinated regulation in patient subgroups. Note, that many more patients show up-regulation as indicated by dark spots in this plot than down-regulation as indicated by dark spots in Figure 14. The known most frequently up-regulated genes in this region are EIF2S2, AHCY, ITCH, DNCL2A, ITG4BP, C20orf24, NDRGL3, RPN2 and CTNNBL1. Also note the gene C20orf110 alias TP53INP2 which is down-regulated in the majority of tumors.
1334229-01-Abstract-p01
[ "Abstract" ]
[ 0 ]
Abstract
2386495-03-Methods-p01
[ "Age,", "age", "at", "diagnosis;", "DL,", "duodenal", "lesion;", "dom,", "dominant;", "FGP,", "fundic", "gland", "polyps;", "NA,", "no", "available", "data;", "NI,", "no", "inheritance;", "Number", "of", "polyps,", "number", "of", "polyps", "at", "diagnosis;", "rec,", "recessive" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Age, age at diagnosis; DL, duodenal lesion; dom, dominant; FGP, fundic gland polyps; NA, no available data; NI, no inheritance; Number of polyps, number of polyps at diagnosis; rec, recessive
1360090-03-Results-p01
[ "a", "Data", "was", "unavailable", "for", "gender", "in", "43", "cases,", "infiltrating", "lymphocytes", "in", "55", "cases,", "nodal", "involvement", "in", "77", "cases,", "tumor", "site", "in", "56", "cases,", "grade", "in", "106", "cases", "and", "mucinous", "appearance", "in", "89", "cases." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
a Data was unavailable for gender in 43 cases, infiltrating lymphocytes in 55 cases, nodal involvement in 77 cases, tumor site in 56 cases, grade in 106 cases and mucinous appearance in 89 cases.
1360090-03-Results-p01
[ "BRAF", "mutations", "showed", "no", "association", "with", "TP53", "mutations", "and", "were", "mutually", "exclusive", "with", "the", "presence", "of", "KRAS", "mutations", "(Table", "2).", "In", "contrast,", "BRAF", "mutations", "were", "approximately", "10-fold", "more", "frequent", "in", "MSI+", "and", "CIMP+", "tumors", "compared", "to", "tumors", "without", "these", "phenotypes.", "A", "strong", "association", "was", "also", "seen", "with", "methylation", "of", "the", "MLH1", "gene", "promoter", "and", "in", "particular", "with", "methylation", "of", "its", "proximal", "region.", "We", "have", "previously", "examined", "the", "methylation", "status", "of", "7", "different", "CpG", "islands", "in", "this", "CRC", "series", "[18].", "The", "mean", "number", "of", "these", "methylated", "sites", "was", "3-fold", "higher", "in", "tumors", "with", "BRAF", "mutation", "compared", "to", "those", "without", "(2.6", "±", "1.7", "vs", "0.8", "±", "1.0;", "P", "<", "0.001).", "Multivariate", "analysis", "revealed", "that", "MSI+", "was", "the", "only", "significant", "independent", "predictor", "of", "BRAF", "mutation", "(RR", "=", "6.3,", "95%CI", "[1.2–32.3];", "P", "=", "0.028)", "in", "a", "model", "that", "included", "CIMP+,", "tumor", "site,", "histological", "grade,", "presence", "of", "infiltrating", "lymphocytes", "and", "mucinous", "appearance." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
BRAF mutations showed no association with TP53 mutations and were mutually exclusive with the presence of KRAS mutations (Table 2). In contrast, BRAF mutations were approximately 10-fold more frequent in MSI+ and CIMP+ tumors compared to tumors without these phenotypes. A strong association was also seen with methylation of the MLH1 gene promoter and in particular with methylation of its proximal region. We have previously examined the methylation status of 7 different CpG islands in this CRC series [18]. The mean number of these methylated sites was 3-fold higher in tumors with BRAF mutation compared to those without (2.6 ± 1.7 vs 0.8 ± 1.0; P < 0.001). Multivariate analysis revealed that MSI+ was the only significant independent predictor of BRAF mutation (RR = 6.3, 95%CI [1.2–32.3]; P = 0.028) in a model that included CIMP+, tumor site, histological grade, presence of infiltrating lymphocytes and mucinous appearance.
3034663-04-Results-p02
[ "Of", "the", "17", "CRC", " ", "patients", "with", "the", "Lys618Ala", "variant,", "two", "had", "MSI", "(11.8%),", "one", "in", "the", "familial", "CRC", "group", "(1/8)", "and", "one", "in", "the", "sporadic", "CRC", "group", "(1/9)." ]
[ 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Of the 17 CRC patients with the Lys618Ala variant, two had MSI (11.8%), one in the familial CRC group (1/8) and one in the sporadic CRC group (1/9).
3034663-03-Methods-p02
[ "Tumours", "from", "p.Lys618Ala", "carrier", "cases", "in", "the", "familial", "group", "(seven", "index", "subjects", "and", "one", "relative)", "were", "also", "analysed", "for", "MLH1", "protein", "expression", "using", "immunohistochemistry", "and", "anti-MLH1", "antibodies", "(PharMingen,", "CA,", "USA)", "as", "described", "elsewhere", "[7].", "Tumour", "cells", "were", "judged", "negative", "for", "protein", "expression", "only", "if", "they", "lacked", "staining", "in", "a", "sample", "in", "which", "normal", "colonocytes", "and", "stroma", "cells", "were", "stained.", "If", "no", "immunostaining", "of", "normal", "tissue", "could", "be", "demonstrated,", "the", "results", "were", "considered", "unreliable." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Tumours from p.Lys618Ala carrier cases in the familial group (seven index subjects and one relative) were also analysed for MLH1 protein expression using immunohistochemistry and anti-MLH1 antibodies (PharMingen, CA, USA) as described elsewhere [7]. Tumour cells were judged negative for protein expression only if they lacked staining in a sample in which normal colonocytes and stroma cells were stained. If no immunostaining of normal tissue could be demonstrated, the results were considered unreliable.
1334229-03-Methods-p01
[ "Tumour", "material", "of", "colorectal", "cancer", "patients", "was", "collected", "after", "approval", "by", "the", "Ethical", "Review", "Board", "of", "Maastricht", "University,", "PALGA", "and", "the", "NCR.", "Tissue", "samples", "from", "819", "colorectal", "cancer", "patients", "were", "localized", "in", "54", "pathology", "laboratories", "throughout", "the", "Netherlands.", "Forty-four", "(", "5%", "incident", "cases", " ", "with", "histologically", "confirmed", "colorectal", "cancer", "were", "identified", "within", "the", "cohort,", "of", "whom", "819", "could", "also", "be", "linked", "to", "a", "PALGA", "report", "of", "the", "lesion." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 9, 10, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Tumour material of colorectal cancer patients was collected after approval by the Ethical Review Board of Maastricht University, PALGA and the NCR. Tissue samples from 819 colorectal cancer patients were localized in 54 pathology laboratories throughout the Netherlands. Forty-four ( 5% incident cases with histologically confirmed colorectal cancer were identified within the cohort, of whom 819 could also be linked to a PALGA report of the lesion.
2386495-05-Discussion-p03
[]
[]
1601966-03-Results-p05
[ "We", "observed", "increased", "expression", "of", "genes", "in", "chromosomal", "region", "12q14.2-12q22", "(see", "Figures", "15,", "16,", "17).", "The", "MDM2", "gene", "at", "12q15", "is", "a", "possible", "target", "of", "this", "misregulation.", "However,", "within", "this", "large", "region", "there", "is", "a", "smaller", "region", "at", "12q21.1-q21.2", "spanning", "eight", "genes", "that", "exhibit", "exceptionally", "high", "expression", "in", "our", "tumor", "samples.", "Among", "these", "is", "LGR5", "alias", "GPR49,", "a", "G-protein", "coupled", "receptor", "that", "has", "large", "leucine-rich", "repeats", "in", "its", "N-terminus.", "We", "could", "confirm", "the", "up-regulation", "of", "GPR49", "in", "CRC", "by", "quantitative", "PCR", "and", "in-situ", "hybridization", "(data", "not", "shown).", "This", "finding", "and", "the", "exceptional", "suitability", "of", "G-protein-coupled", "receptors", "as", "drug", "targets", "make", "the", "LGR5", "TP53INP2", "patients", " ", "with", "consistent", "up-regulation", "in", "two", "genes", "are", "coded", "by", "different", "shades", "of", "gray.", "Dark", "squared", "regions", "along", "the", "diagonal", "indicate", "coordinated", "regulation", "in", "patient", "subgroups.", "Note,", "that", "many", "more", "patients", " ", "show", "up-regulation", "as", "indicated", "by", "dark", "spots", "in", "this", "plot", "than", "down-regulation", "as", "indicated", "by", "dark", "spots", "in", "Figure", "14.", "The", "known", "most", "frequently", "up-regulated", "genes", "in", "this", "region", "are", "EIF2S2,", "AHCY,", "ITCH,", "DNCL2A,", "ITG4BP,", "C20orf24,", "NDRGL3,", "RPN2", "and", "CTNNBL1.", "Also", "note", "the", "gene", "C20orf110", "alias", "TP53INP2", "which", "is", "down-regulated", "in", "the", "majority", "of", "tumors." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 21, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
We observed increased expression of genes in chromosomal region 12q14.2-12q22 (see Figures 15, 16, 17). The MDM2 gene at 12q15 is a possible target of this misregulation. However, within this large region there is a smaller region at 12q21.1-q21.2 spanning eight genes that exhibit exceptionally high expression in our tumor samples. Among these is LGR5 alias GPR49, a G-protein coupled receptor that has large leucine-rich repeats in its N-terminus. We could confirm the up-regulation of GPR49 in CRC by quantitative PCR and in-situ hybridization (data not shown). This finding and the exceptional suitability of G-protein-coupled receptors as drug targets make the LGR5 TP53INP2 patients with consistent up-regulation in two genes are coded by different shades of gray. Dark squared regions along the diagonal indicate coordinated regulation in patient subgroups. Note, that many more patients show up-regulation as indicated by dark spots in this plot than down-regulation as indicated by dark spots in Figure 14. The known most frequently up-regulated genes in this region are EIF2S2, AHCY, ITCH, DNCL2A, ITG4BP, C20orf24, NDRGL3, RPN2 and CTNNBL1. Also note the gene C20orf110 alias TP53INP2 which is down-regulated in the majority of tumors.
3034663-04-Results-p01
[ "The", "p.Lys618Ala", "variant", "was", "present", "in", "the", "third", "family", "that", "fulfilled", "the", "Amsterdam", "II", "Criteria.", "A", "first-grade", "familiar", "non-carrier", "of", "this", "variant", "was", "diagnosed", "with", "a", "colonic", "polyp", "with", "a", "high", "grade", "of", "dysplasia", " ", "at", "the", "age", "of", "39", "years", "and", "with", "four", "colonic", " ", "polyps", "sporadic", " ", "group", "(9/373,", "2.41%)", "and", "seven", "were", "CRC", "patients", "from", "the", "familial", " ", "group", "(7/250,", "2.8%).", "None", "of", "the", "individuals", "was", "homozygous", "for", "the", "minor", "allele." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 19, 20, 20, 20, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 1, 17, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 17, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The p.Lys618Ala variant was present in the third family that fulfilled the Amsterdam II Criteria. A first-grade familiar non-carrier of this variant was diagnosed with a colonic polyp with a high grade of dysplasia at the age of 39 years and with four colonic polyps sporadic group (9/373, 2.41%) and seven were CRC patients from the familial group (7/250, 2.8%). None of the individuals was homozygous for the minor allele.
1619718-05-Discussion-p02
[ "Non-dysplastic", "serrated", "polyps:", "HP", "and", "SSA" ]
[ 0, 0, 0, 0, 0, 0 ]
Non-dysplastic serrated polyps: HP and SSA
3034663-04-Results-p01
[ "Allelic", "and", "genotypic", "frequencies", "and", "Hardy-Weinberg", "equilibrium" ]
[ 0, 0, 0, 0, 0, 0, 0 ]
Allelic and genotypic frequencies and Hardy-Weinberg equilibrium
1334229-01-Abstract-p01
[ "In", "a", "group", "of", "656", "unselected", "sporadic", " ", "colorectal", "cancer", "patients,", "aberrations", "in", "the", "APC,", "K-ras,", "CTNNB1", "genes,", "and", "expression", "of", "hMLH1", "were", "investigated.", "Additionally,", "tumours", "were", "divided", "in", "groups", "based", "on", "molecular", "features", "and", "compared", "with", "respect", "to", "patient's", "age", "at", "diagnosis,", "sex,", "family", "history", "of", "colorectal", "cancer,", "tumour", "sub-localisation,", "Dukes'", "stage", "and", "differentiation." ]
[ 0, 0, 0, 0, 0, 0, 17, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In a group of 656 unselected sporadic colorectal cancer patients, aberrations in the APC, K-ras, CTNNB1 genes, and expression of hMLH1 were investigated. Additionally, tumours were divided in groups based on molecular features and compared with respect to patient's age at diagnosis, sex, family history of colorectal cancer, tumour sub-localisation, Dukes' stage and differentiation.
1373649-03-Methods-p01
[ "Pedigree", "showing", "HNPCC", "family.", "An", "arrow", "indicates", "the", "male", "index", "patient", "(III:3)", "diagnosed", "with", "colorectal", "adenocarcinoma", "at", "the", "age", "of", "23", "years.", "Family", "members", "suffering", "from", "a", "malignancy", "are", "indicated", "by", "a", "shaded", "circle", "or", "square.", "The", "age,", "type", "of", "malignancy,", "as", "well", "as", "the", "generation", "(roman", "figures),", "are", "described", "below", "the", "indicated", "patient.", "The", "family", "fulfill", "the", "Amsterdam-I", "criteria", "with", "presence", "of", "extracolonic", "tumors", "in", "the", "extended", "pedigree,", "having", "more", "than", "three", "carcinomas", "of", "colon", "(C)", "or", "ovary", "(O)", "in", "the", "affected", "members.", "The", "syndrome", "is", "present", "in", "all", "three", "generations", "(I-III)", "and", "three", "family", "members", "are", "younger", "than", "50", "years", "(III:3,", "II:1", "and", "I:3).", "At", "the", "moment", "of", "the", "study", "the", "proband's", "mother", "(II-5)", "was", "an", "unaffected", "carrier,", "but", "two", "years", "later", "she", "developed", "an", "endometrial", "(E)", "adenocarcinoma." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Pedigree showing HNPCC family. An arrow indicates the male index patient (III:3) diagnosed with colorectal adenocarcinoma at the age of 23 years. Family members suffering from a malignancy are indicated by a shaded circle or square. The age, type of malignancy, as well as the generation (roman figures), are described below the indicated patient. The family fulfill the Amsterdam-I criteria with presence of extracolonic tumors in the extended pedigree, having more than three carcinomas of colon (C) or ovary (O) in the affected members. The syndrome is present in all three generations (I-III) and three family members are younger than 50 years (III:3, II:1 and I:3). At the moment of the study the proband's mother (II-5) was an unaffected carrier, but two years later she developed an endometrial (E) adenocarcinoma.
1334229-04-Results-p02
[ "When", "comparing", "tumours", "with", "a", "missense", "(but", "not", "a", "truncating)", "mutation", "in", "APC", "to", "tumours", "with", "a", "truncating", "mutation", "in", "APC,", "missense", "mutations", "occurred", "relatively", "more", "frequently", "in", "the", "colon", "(P", "=", "0.002),", "less", "often", "also", "harboured", "an", "activating", "K-ras", "mutation", "(P", "=", "0.004),", "and", "more", "often", "also", "lacked", "hMLH1", "expression", "(P", "<", "0.001).", "No", "differences", "were", "observed", "with", "regard", "to", "age", "at", "diagnosis,", "gender,", "Dukes'", "stage", "or", "tumour", "tumours", " ", "with", "a", "truncating", "mutation", "in", "APC,", "missense", "mutations", "occurred", "relatively", "more", "frequently", "in", "the", "colon", "(P", "=", "0.002),", "less", "often", "also", "harboured", "an", "activating", "K-ras", "mutation", "(P", "=", "0.004),", "and", "more", "often", "also", "lacked", "hMLH1", "expression", "(P", "<", "0.001).", "No", "differences", "were", "observed", "with", "regard", "to", "age", "at", "diagnosis,", "gender,", "Dukes'", "stage", "or", "tumour", "differentiation", "(data", "not", "shown)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
When comparing tumours with a missense (but not a truncating) mutation in APC to tumours with a truncating mutation in APC, missense mutations occurred relatively more frequently in the colon (P = 0.002), less often also harboured an activating K-ras mutation (P = 0.004), and more often also lacked hMLH1 expression (P < 0.001). No differences were observed with regard to age at diagnosis, gender, Dukes' stage or tumour tumours with a truncating mutation in APC, missense mutations occurred relatively more frequently in the colon (P = 0.002), less often also harboured an activating K-ras mutation (P = 0.004), and more often also lacked hMLH1 expression (P < 0.001). No differences were observed with regard to age at diagnosis, gender, Dukes' stage or tumour differentiation (data not shown).
2275286-03-Methods-p03
[ "Primers", "for", "all", "exons", "of", "MSH2,", "MLH1", "and", "MSH6", "were", "designed", "for", "PCR", "amplification", "as", "previously", "reported.", "PCR", "amplification", "was", "performed", "using", "the", "reagents", "from", "ABI", "Company,", "following", "the", "protocol", "provided", "by", "the", "company.", "After", "amplification,", "the", "PCR", "products", "were", "purified", "by", "electrophoresis", "through", "a", "1.5%", "low", "melting", "point", "agarose", "gel,", "and", "then", "were", "sequenced", "on", "an", "AB13100-Avant", "sequencer", "(Applied", "Biosystem", "Shanghai", "Division)", "using", "fluorescently", "labeled", "primers,", "following", "the", "protocols", "supplied", "by", "the", "manufacturer.", "By", "comparing", "the", "obtained", "sequence", "with", "the", "known", "sequence,", "nonsense,", "missense,", "and", "frameshift", "mutations", "were", "identified.", "Nonsense", "and", "frameshift", "mutations", "were", "considered", "pathogenic.", "All", "missense", "mutations", "were", "screened", "in", "50", "patients", "with", "MSS", " ", "colorectal", "cancer", "and", "50", "people", "without", "cancer", "or", "a", "family", "history", "of", "cancer.", "They", "were", "judged", "as", "pathogenic", "if", "they", "could", "not", "be", "found", "in", "MSS", "patients", "and", "normal", "people,", "otherwise,", "they", "were", "judged", "as", "polymorphisms." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 19, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Primers for all exons of MSH2, MLH1 and MSH6 were designed for PCR amplification as previously reported. PCR amplification was performed using the reagents from ABI Company, following the protocol provided by the company. After amplification, the PCR products were purified by electrophoresis through a 1.5% low melting point agarose gel, and then were sequenced on an AB13100-Avant sequencer (Applied Biosystem Shanghai Division) using fluorescently labeled primers, following the protocols supplied by the manufacturer. By comparing the obtained sequence with the known sequence, nonsense, missense, and frameshift mutations were identified. Nonsense and frameshift mutations were considered pathogenic. All missense mutations were screened in 50 patients with MSS colorectal cancer and 50 people without cancer or a family history of cancer. They were judged as pathogenic if they could not be found in MSS patients and normal people, otherwise, they were judged as polymorphisms.
1619718-04-Results-p01
[ "KRAS", "mutation", "occurred", "in", "26.5%", "and", "BRAF", "mutation", "in", "4.8%", "of", "adenomas", "(all", "types)", "(Table", "1)", "(P", "<", "0.0001).", "TVAs/VAs", " ", "were", "more", "likely", "to", "have", "KRAS", "mutation", "(50%)", "than", "TAs", "<", " ", "10", "mm", " ", "(18%)", "(P", "<", "0.004)", "or", "TAS", "one", " ", "SSA).", "The", "three", "conventional", "adenomas", "with", "mutations", "of", "both", "BRAF", "and", "KRAS", "were", "among", "only", "four", "adenomas", "that", "had", "any", "BRAF", "mutations", "at", "all.", "Mutation", "frequencies", "for", "both", "KRAS", "and", "BRAF", "were", "distributed", "differently", "across", "the", "seven", "polyp", "groups", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
KRAS mutation occurred in 26.5% and BRAF mutation in 4.8% of adenomas (all types) (Table 1) (P < 0.0001). TVAs/VAs were more likely to have KRAS mutation (50%) than TAs <   10 mm (18%) (P < 0.004) or TAS one SSA). The three conventional adenomas with mutations of both BRAF and KRAS were among only four adenomas that had any BRAF mutations at all. Mutation frequencies for both KRAS and BRAF were distributed differently across the seven polyp groups (Table 1).
2275286-04-Results-p02
[ "The", "mutation", "between", "the", "MSI-L", "and", "MSI-H" ]
[ 0, 0, 0, 0, 0, 0, 0 ]
The mutation between the MSI-L and MSI-H
1601966-03-Results-p11
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1373649-03-Methods-p01
[ "The", "early", "onset", "of", "the", "colon", "cancer", "in", "the", "proband", "and", "the", "study", "of", "the", "family's", "pedigree", "(fig.", "1),", "that", "fulfill", "the", "strict", "Amsterdam-1", "criteria,", "prompted", "genetic", "analysis", "with", "suspicion", "of", "HNPCC.", "They", "were", "informed", "about", "the", "risks,", "benefits", "and", "limitations", "of", "the", "study", "protocol." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The early onset of the colon cancer in the proband and the study of the family's pedigree (fig. 1), that fulfill the strict Amsterdam-1 criteria, prompted genetic analysis with suspicion of HNPCC. They were informed about the risks, benefits and limitations of the study protocol.
2386495-01-Abstract-p01
[ "Mutation", "screening", "of", "APC", "and", "the", "clinical", "characterization", "of", "96", "unrelated", "FAP", "patients", "from", "the", "Swedish", " ", "Polyposis", "Registry", "was", "performed.", "In", "addition", "to", "generally", "used", "mutation", "screening", "methods,", "analyses", "of", "splicing-affecting", "mutations", "and", "investigations", "of", "the", "presence", "of", "low-frequency", "mutation", "alleles,", "indicating", "mosaics,", "have", "been", "performed,", "as", "well", "as", "quantitative", "real-time", "polymerase", "chain", "reaction", "to", "detect", "lowered", "expression", "of", "APC." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 25, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Mutation screening of APC and the clinical characterization of 96 unrelated FAP patients from the Swedish Polyposis Registry was performed. In addition to generally used mutation screening methods, analyses of splicing-affecting mutations and investigations of the presence of low-frequency mutation alleles, indicating mosaics, have been performed, as well as quantitative real-time polymerase chain reaction to detect lowered expression of APC.
1266026-05-Discussion-p01
[ "In", "agreement", "with", "prior", "studies,", "there", "were", "seven", "mutations", "estimated", "for", "sporadic", "MSI-", "Finnish", "cancers", "[4],", "and", "seven", "or", "eight", "mutations", "for", "MSI+", "cancers", "seven", "or", "eight", "MSI+", " ", "cancers", "were", "further", "sub-classified", "as", "either", "hereditary", "(HNPCC)", "or", "sporadic.", "As", "expected", "because", "one", "MMR", "mutation", "is", "inherited,", "estimated", "numbers", "of", "critical", "mutations", "were", "less", "for", "MSI+", "HNPCC", "cancers", "compared", "to", "sporadic", "MSI+", "cancers.", "However,", "sporadic", "MSI+", "cancers", "required", "more", "than", "one", "additional", "somatic", "mutation", "compared", "to", "HNPCC", "cancers.", "Of", "interest,", "a", "difference", "of", "more", "than", "a", "single", "mutation", "has", "also", "been", "inferred", "between", "sporadic", "and", "FAP", "cancers,", "with", "estimates", "of", "three", "to", "four", "mutations", "for", "FAP", "cancers", "versus", "six", "for", "sporadic", "cancers", "[6,13],", "although", "another", "analysis", "was", "consistent", "with", "a", "difference", "of", "only", "a", "single", "mutation", "[14].", "Therefore,", "germline", "mutations", "(APC", "and", "MMR", "loci)", "in", "both", "common", "colorectal", "familial", "cancer", "syndromes", "(FAP", "and", "HNPCC)", "appear", "to", "advance", "progression", "by", "more", "than", "a", "single", "mutation", "relative", "to", "their", "sporadic", "counterparts." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 11, 12, 12, 19, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In agreement with prior studies, there were seven mutations estimated for sporadic MSI- Finnish cancers [4], and seven or eight mutations for MSI+ cancers seven or eight MSI+ cancers were further sub-classified as either hereditary (HNPCC) or sporadic. As expected because one MMR mutation is inherited, estimated numbers of critical mutations were less for MSI+ HNPCC cancers compared to sporadic MSI+ cancers. However, sporadic MSI+ cancers required more than one additional somatic mutation compared to HNPCC cancers. Of interest, a difference of more than a single mutation has also been inferred between sporadic and FAP cancers, with estimates of three to four mutations for FAP cancers versus six for sporadic cancers [6,13], although another analysis was consistent with a difference of only a single mutation [14]. Therefore, germline mutations (APC and MMR loci) in both common colorectal familial cancer syndromes (FAP and HNPCC) appear to advance progression by more than a single mutation relative to their sporadic counterparts.
1373649-03-Methods-p01
[ "Pedigree", "showing", "HNPCC", "family.", "An", "arrow", "indicates", "the", "male", "index", "patient", "(III:3)", "diagnosed", "with", "colorectal", "adenocarcinoma", "at", "the", "age", "of", "23", "years", ".", "Family", "members", "suffering", "from", "a", "malignancy", "are", "indicated", "by", "a", "shaded", "circle", "or", "square.", "The", "age,", "type", "of", "malignancy,", "as", "well", "as", "the", "generation", "(roman", "figures),", "are", "described", "below", "the", "indicated", "patient.", "The", "family", "fulfill", "the", "Amsterdam-I", "criteria", "with", "presence", "of", "extracolonic", "tumors", "index", "patient", " ", "(III:3)", "diagnosed", "with", "colorectal", "adenocarcinoma", "at", "the", "age", "of", "23", "years.", "Family", "members", "suffering", "from", "a", "malignancy", "are", "indicated", "by", "a", "shaded", "circle", "or", "square.", "The", "age,", "type", "of", "malignancy,", "as", "well", "as", "the", "generation", "(roman", "figures),", "are", "described", "below", "the", "indicated", "patient.", "The", "family", "fulfill", "the", "Amsterdam-I", "criteria", "with", "presence", "of", "extracolonic", "tumors", "in", "the", "extended", "pedigree,", "having", "more", "than", "three", "carcinomas", "of", "colon", "(C)", "or", "ovary", "(O)", "in", "the", "affected", "members.", "The", "syndrome", "is", "present", "in", "all", "three", "generations", "(I-III)", "and", "three", "family", "members", "are", "younger", "than", "50", "years", "(III:3,", "II:1", "and", "I:3).", "At", "the", "moment", "of", "the", "study", "the", "proband's", "mother", "(II-5)", "was", "an", "unaffected", "carrier,", "but", "two", "years", "later", "she", "developed", "an", "endometrial", "(E)", "adenocarcinoma." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 15, 16, 16, 16, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 9, 10, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Pedigree showing HNPCC family. An arrow indicates the male index patient (III:3) diagnosed with colorectal adenocarcinoma at the age of 23 years . Family members suffering from a malignancy are indicated by a shaded circle or square. The age, type of malignancy, as well as the generation (roman figures), are described below the indicated patient. The family fulfill the Amsterdam-I criteria with presence of extracolonic tumors index patient (III:3) diagnosed with colorectal adenocarcinoma at the age of 23 years. Family members suffering from a malignancy are indicated by a shaded circle or square. The age, type of malignancy, as well as the generation (roman figures), are described below the indicated patient. The family fulfill the Amsterdam-I criteria with presence of extracolonic tumors in the extended pedigree, having more than three carcinomas of colon (C) or ovary (O) in the affected members. The syndrome is present in all three generations (I-III) and three family members are younger than 50 years (III:3, II:1 and I:3). At the moment of the study the proband's mother (II-5) was an unaffected carrier, but two years later she developed an endometrial (E) adenocarcinoma.
3034663-03-Methods-p01
[ "We", "genotyped", "the", "p.Lys618Ala", "variant", "in", "MLH1", "in", "1034", "individuals", "(373", "sporadic", "CRC", " ", "patients,", "250", "index", "subjects", "from", "families", "suspected", "of", "having", "LS", "[revised", "Bethesda", "Guidelines]", "and", "411", "controls).", "The", "controls", "were", "selected", "from", "the", "same", "hospitals,", "had", "no", "personal", "histories", "of", "cancer", "and", "had", "diagnoses", "unrelated", "to", "the", "variables", "of", "interest.", "They", "were", "matched", "for", "age,", "gender", "and", "race/ethnicity", "with", "the", "sporadic", "CRC", "patients." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
We genotyped the p.Lys618Ala variant in MLH1 in 1034 individuals (373 sporadic CRC patients, 250 index subjects from families suspected of having LS [revised Bethesda Guidelines] and 411 controls). The controls were selected from the same hospitals, had no personal histories of cancer and had diagnoses unrelated to the variables of interest. They were matched for age, gender and race/ethnicity with the sporadic CRC patients.
1619718-04-Results-p02
[ "With", "respect", "to", "the", "25", "serrated", "polyps", "with", "dysplasia,", "only", "five", "occurred", "in", "the", "proximal", "colon", "(up", "to", "the", "splenic", "flexure).", "Two", "of", "these", "had", "BRAF", "mutation", "(both", "Group", "A)", "and", "two", " ", "had", "KRAS", "mutation", "(both", "Group", "B).", "Seven", "of", "the", "11", "BRAF", "mutations", "occurred", "in", "polyps", "derived", "from", "the", "left", "colon", "or", "rectum", "(remaining", "two", "polyps", "with", "BRAF", "mutation", "from", "site", "unknown).", "The", "three", "Group", "A", "SAs", "with", "KRAS", "mutation", "(all", "from", "the", "left", "colon", "or", "rectum)", "comprised", "numerous", "goblet", "cells", "and", "adjacent", "cells", "with", "eosinophilic", "cytoplasm", "and", "no", "mucin", "production", "or", "microvesicular", "appearance", "(Figure", "1E,F).", "These", "SAs", "therefore", "resembled", "the", "goblet", "cell", "variant", "of", "HP." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
With respect to the 25 serrated polyps with dysplasia, only five occurred in the proximal colon (up to the splenic flexure). Two of these had BRAF mutation (both Group A) and two had KRAS mutation (both Group B). Seven of the 11 BRAF mutations occurred in polyps derived from the left colon or rectum (remaining two polyps with BRAF mutation from site unknown). The three Group A SAs with KRAS mutation (all from the left colon or rectum) comprised numerous goblet cells and adjacent cells with eosinophilic cytoplasm and no mucin production or microvesicular appearance (Figure 1E,F). These SAs therefore resembled the goblet cell variant of HP.
1373649-04-Results-and-discussion-p01
[ "DNA", "sequence", "analysis", "of", "hMSH2", "exon", "12.", "Genomic", "DNA", "was", "isolated", "from", "leucocytes", "and", "PCR", "amplified", "with", "the", "help", "of", "hMSH2", "exon", "12", "flanking", "primers.", "In", "the", "image", "the", "result", "of", "the", "sequencing", "using", "the", "PCR", "forward", "primer.", "Panel", "A:", "proband's", "mother", "(obligate", "carrier),", "positive", "for", "the", "mutation.", "Panel", "B:", "negative", "control", "for", "the", "mutation." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
DNA sequence analysis of hMSH2 exon 12. Genomic DNA was isolated from leucocytes and PCR amplified with the help of hMSH2 exon 12 flanking primers. In the image the result of the sequencing using the PCR forward primer. Panel A: proband's mother (obligate carrier), positive for the mutation. Panel B: negative control for the mutation.
3034663-03-Methods-p01
[ "Genotyping", "of", "the", "MLH1", "p.Lys618Ala", "p.Lys618Ala", "71", "years", " ", "(range,", "25-96", "years)", "for", "the", "controls", ".", "The", "sex", "distribution", "was", "58%", "men", "and", "42%", "women", "for", "the", "sporadic", "CRC", "group", "and", "53.3%", "men", " ", "and", "46.7%", "women", "for", "the", "controls." ]
[ 0, 0, 0, 0, 5, 5, 15, 16, 0, 0, 0, 0, 0, 0, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 0, 0, 0, 0, 0, 0, 0 ]
Genotyping of the MLH1 p.Lys618Ala p.Lys618Ala 71 years (range, 25-96 years) for the controls . The sex distribution was 58% men and 42% women for the sporadic CRC group and 53.3% men and 46.7% women for the controls.
1619718-01-Abstract-p01
[ "To", "establish", "and", "explain", "the", "pattern", "of", "molecular", "signatures", "across", "colorectal", "polyps." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
To establish and explain the pattern of molecular signatures across colorectal polyps.
1334229-03-Methods-p02
[ "The", "semi-nested", "PCR", "products", "from", "samples", "without", "a", "truncating", "APC", "mutation", "were", "screened", "for", "mutations", "using", "denaturing", "high-pressure", "liquid", "chromatography", "(dHPLC)", "on", "a", "WAVE", "3500", "HT", "system", "(Transgenomic", "Inc.,", "UK).", "WAVE", "analysis", "was", "optimised", "and", "validated", "using", "specific", "mutations", "in", "cell", "line", "DNA,", "i.e.", "HCT116", "(codon", "45:", "3", "bp", "deletion)", "and", "SW48", "(codon", "33:", "C→A)", "as", "well", "as", "DNA", "derived", "from", "desmoid", "tumours", "from", "patients", "patients", " ", "were", "not", "included", "in", "this", "study." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 9, 0, 0, 0, 0, 0, 0, 0 ]
The semi-nested PCR products from samples without a truncating APC mutation were screened for mutations using denaturing high-pressure liquid chromatography (dHPLC) on a WAVE 3500 HT system (Transgenomic Inc., UK). WAVE analysis was optimised and validated using specific mutations in cell line DNA, i.e. HCT116 (codon 45: 3 bp deletion) and SW48 (codon 33: C→A) as well as DNA derived from desmoid tumours from patients patients were not included in this study.
1619718-02-Introduction-p01
[ "In", "recent", "years,", "the", "fundamental", "division", "of", "colorectal", "polyps", "into", "precancerous", "colorectal", "carcinoma", " ", "sequence,", "with", "its", "accompanying", "genetic", "steps,", "provides", "a", "surprisingly", "narrow", "window", "of", "understanding", "of", "this", "multipathway", "reality.9" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 17, 3, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
In recent years, the fundamental division of colorectal polyps into precancerous colorectal carcinoma sequence, with its accompanying genetic steps, provides a surprisingly narrow window of understanding of this multipathway reality.9
1601966-03-Results-p04
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
2275286-03-Methods-p03
[ "The", "sequences", "of", "primers", "and", "the", "fluorogenic", "probe", "were", "designed", "by", "MethPrimer", "software.", "Primer", "sequence", "for", "hMLH1", "was:", "CGTTATATATCGTTCGTAGTATTCGTGTTT(Forward),", "and", "CTATCGCCGCCTCATCGT", "(Reverse),", "probe", "sequence", "was", "6FAM-CGCGACGTCAAACGCCACTACG-TAMRA.", "For", "the", "MSP,", "5", "μL", "of", "bisulfite-converted", "DNA", "was", "used", "in", "each", "amplification.", "PCR", "was", "performed", "in", "a", "reaction", "volume", "of", "25", "μL", "consisting", "of", "5", "pmol", "of", "each", "primer,", "250", "pmol", "of", "probe,", "200", "μM", "each", "of", "dATP,", "dCTP,", "and", "dGTP,", "400", "μM", "dUTP,", "3.5", "mM", "MgCl2,", "1×", "TaqMan", "Buffer", "A,", "and", "2", "units", "of", "AmpliTaq", "Gold", "polymerase", "(Applied", "Biosystem", "Shanghai", "Division,", "Shanghai,", "China)", "at", "the", "following", "condition:", "95°C", "for", "10", "min,", "followed", "by", "50", "cycles", "at", "95°C", "for", "15", "s,", "and", "60°C", "for", "1", "min.", "All", "PCR", "was", "performed", "in", "the", "ABI-7000", "Real-Time", "PCR", "Detection", "system", "(Applied", "Biosystem", "Shanghai", "Division,", "Shanghai,", "China).", "CpGenomeTM", "Universal", "methylated", "DNA", "(Chemicon", "International", "Inc.,", "city,", "CA,", "USA)", "was", "included", "as", "positive", "control", "in", "all", "amplifications", "and", "glyceraldehyde-3-phosphate", "dehydrogenase", "(GAPDH)", "quantification", "of", "all", "untreated", "DNA", "was", "used", "as", "loading", "control." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The sequences of primers and the fluorogenic probe were designed by MethPrimer software. Primer sequence for hMLH1 was: CGTTATATATCGTTCGTAGTATTCGTGTTT(Forward), and CTATCGCCGCCTCATCGT (Reverse), probe sequence was 6FAM-CGCGACGTCAAACGCCACTACG-TAMRA. For the MSP, 5 μL of bisulfite-converted DNA was used in each amplification. PCR was performed in a reaction volume of 25 μL consisting of 5 pmol of each primer, 250 pmol of probe, 200 μM each of dATP, dCTP, and dGTP, 400 μM dUTP, 3.5 mM MgCl2, 1× TaqMan Buffer A, and 2 units of AmpliTaq Gold polymerase (Applied Biosystem Shanghai Division, Shanghai, China) at the following condition: 95°C for 10 min, followed by 50 cycles at 95°C for 15 s, and 60°C for 1 min. All PCR was performed in the ABI-7000 Real-Time PCR Detection system (Applied Biosystem Shanghai Division, Shanghai, China). CpGenomeTM Universal methylated DNA (Chemicon International Inc., city, CA, USA) was included as positive control in all amplifications and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) quantification of all untreated DNA was used as loading control.
1360090-04-Discussion-p01
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1557864-03-Methods-p02
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1619718-05-Discussion-p03
[ "Colorectal", "polyps", "have", "traditionally", "been", "classified", "into", "distinct", "histogenetic", "types", "that", "may", "progress", "to", "CRC", "through", "independent", "pathways", "of", "colorectal", "tumorigenesis", "(Table", "2).", "However,", "in", "addition", "to", "the", "two", "‘classical’", "pathways", "to", "CRC", " ", "shown", "in", "Table", "2,", "there", "may", "be", "‘fusion’", "pathways", "that", "combine", "mechanisms", "associated", "with", "both", "adenomas", "and", "serrated", "polyps.", "This", "would", "explain", "why", "many", "CRCs", "goblet", "cell", "variant", " ", "of", "HP", " ", "in", "which", "columnar", "cells", "are", "eosinophilic", "and", "lack", "mucin-filled", "microvesicles", "and", "KRAS", "mutation", "is", "frequent", "(Figure", "1E,F).16,25", "The", "literature", "refers", "to", "the", "concept", "of", "‘traditional’", "SA.43", "Based", "on", "the", "current", "findings,", "it", "is", "likely", "that", "several", "mechanisms", "can", "account", "for", "adenomatous", "lesions", "with", "glandular", "serration", "and", "that", "‘traditional’", "SA", "is", "not", "a", "single", "entity." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 17, 18, 18, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Colorectal polyps have traditionally been classified into distinct histogenetic types that may progress to CRC through independent pathways of colorectal tumorigenesis (Table 2). However, in addition to the two ‘classical’ pathways to CRC shown in Table 2, there may be ‘fusion’ pathways that combine mechanisms associated with both adenomas and serrated polyps. This would explain why many CRCs goblet cell variant of HP in which columnar cells are eosinophilic and lack mucin-filled microvesicles and KRAS mutation is frequent (Figure 1E,F).16,25 The literature refers to the concept of ‘traditional’ SA.43 Based on the current findings, it is likely that several mechanisms can account for adenomatous lesions with glandular serration and that ‘traditional’ SA is not a single entity.
1619718-05-Discussion-p04
[ "Loss", "of", "expression", "of", "the", "DNA", "repair", "gene", "MGMT", "is", "associated", "with", "methylation", "of", "the", "promoter", "region45,51,52", "and", "the", "latter", "change", "has", "been", "linked", "causatively", "with", "G:C", "to", "A:T", "transition", "mutations", "in", "TP53.53", "In", "the", "present", "study,", "complete", "or", "partial", "loss", "of", "expression", "of", "MGMT", "coincided", "with", "aberrant", "nuclear", "expression", "of", "p53", "in", "three", "serrated", "polyps", "with", "dysplasia", "(Figure", "2),", "but", "not", "in", "the", "single", "tubular", "adenoma", "with", "aberrant", "p53", "expression.", "Only", "one", "previous", "study", "has", "attempted", "to", "correlate", "MGMT", "and", "p53", "expression", "in", "colorectal", "polyps.45", "In", "that", "study,", "4.3%", "of", "adenomas", "showed", "aberrant", "p53", "expression", "but", "none", "had", "loss", "of", "MGMT.", "It", "is", "possible", "that", "the", "link", "between", "MGMT", "silencing", "and", "TP53", "mutation", "is", "more", "evident", "in", "the", "serrated", "pathway", "than", "in", "the", "adenoma–", "carcinoma", "p53", "expression", "KRAS", " ", "and", "TP53.9", "Partial", "methylation", "of", "MLH1", "may", "also", "lead", "to", "low-level", "microsatellite", "instability.37" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 7, 8, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Loss of expression of the DNA repair gene MGMT is associated with methylation of the promoter region45,51,52 and the latter change has been linked causatively with G:C to A:T transition mutations in TP53.53 In the present study, complete or partial loss of expression of MGMT coincided with aberrant nuclear expression of p53 in three serrated polyps with dysplasia (Figure 2), but not in the single tubular adenoma with aberrant p53 expression. Only one previous study has attempted to correlate MGMT and p53 expression in colorectal polyps.45 In that study, 4.3% of adenomas showed aberrant p53 expression but none had loss of MGMT. It is possible that the link between MGMT silencing and TP53 mutation is more evident in the serrated pathway than in the adenoma– carcinoma p53 expression KRAS and TP53.9 Partial methylation of MLH1 may also lead to low-level microsatellite instability.37
1601966-03-Results-p04
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
1266026-05-Discussion-p01
[ "An", "epigenetic", "mechanism", "may", "help", "explain", "why", "sporadic", "MSI+", "cancers", "require", "more", "than", "one", "additional", "somatic", "alteration", "relative", "to", "HNPCC", "cancers.", "Inactivation", "of", "the", "normal", "MMR", "allele", "occurs", "through", "mutation", "(usually", "LOH", "[15])", "in", "HNPCC", "whereas", "MMR", "loss", "in", "sporadic", "MSI+", "cancers", "is", "associated", "with", "MLH1", "promoter", "methylation", "[16,17].", "CpG", "islands", "may", "be", "\"protected\"", "from", "methylation", "because", "most", "are", "unmethylated", "at", "birth", "and", "usually", "remain", "unmethylated", "throughout", "life", "[18].", "Epigenetic", "MLH1", "inactivation", "may", "require", "at", "least", "two", "cis", "acting", "somatic", "alterations---loss", "of", "a", "mechanism", "that", "normally", "prevents", "methylation,", "followed", "by", "the", "accumulation", "of", "methylation", "at", "sufficient", "numbers", "of", "CpG", "sites", "to", "silence", "expression." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
An epigenetic mechanism may help explain why sporadic MSI+ cancers require more than one additional somatic alteration relative to HNPCC cancers. Inactivation of the normal MMR allele occurs through mutation (usually LOH [15]) in HNPCC whereas MMR loss in sporadic MSI+ cancers is associated with MLH1 promoter methylation [16,17]. CpG islands may be "protected" from methylation because most are unmethylated at birth and usually remain unmethylated throughout life [18]. Epigenetic MLH1 inactivation may require at least two cis acting somatic alterations---loss of a mechanism that normally prevents methylation, followed by the accumulation of methylation at sufficient numbers of CpG sites to silence expression.
2386495-06-Conclusion-p01
[]
[]
2386495-05-Discussion-p04
[ "Mutation-detection", "frequency" ]
[ 0, 0 ]
Mutation-detection frequency
3034663-03-Methods-p02
[ "Tumours", "from", "p.Lys618Ala", "carrier", "cases", "in", "the", "familial", "group", "(seven", "index", "subjects", "and", "one", "relative)", "were", "also", "analysed", "for", "MLH1", "protein", "expression", "using", "immunohistochemistry", "and", "anti-MLH1", "antibodies", "(PharMingen,", "CA,", "USA)", "as", "described", "elsewhere", "[7].", "Tumour", "cells", "were", "judged", "negative", "for", "protein", "expression", "only", "if", "they", "lacked", "staining", "in", "a", "sample", "in", "which", "normal", "colonocytes", "and", "stroma", "cells", "were", "stained.", "If", "no", "immunostaining", "of", "normal", "tissue", "could", "be", "demonstrated,", "the", "results", "were", "considered", "unreliable." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Tumours from p.Lys618Ala carrier cases in the familial group (seven index subjects and one relative) were also analysed for MLH1 protein expression using immunohistochemistry and anti-MLH1 antibodies (PharMingen, CA, USA) as described elsewhere [7]. Tumour cells were judged negative for protein expression only if they lacked staining in a sample in which normal colonocytes and stroma cells were stained. If no immunostaining of normal tissue could be demonstrated, the results were considered unreliable.
2386495-05-Discussion-p03
[ "APC", "mutational", "mosaicism", "could", "be", "a", "reason", "for", "the", "quite", "large", "number", "of", "de", "novo", "or", "sporadic", "FAP", "cases", "that", "exist", "[23-25,40].", "In", "the", "family", "of", "C107", "the", "mutation", "has", "not", "been", "passed", "on", "to", "the", "offspring", "of", "the", "patient", "and,", "thus,", "this", "appears", "to", "be", "a", "sporadic", "case,", "but,", "generally,", "the", "existence", "of", "mosaicism", "is", "a", "risk", "of", "error", "in", "predictive", "diagnosis", "in", "FAP/AFAP", "families", "[43].", "In", "the", "initial", "stages,", "the", "molecular", "screening", "procedure", "of", "FAP/AFAP", "patients", "uses", "mainly", "PCR-based", "methods", "for", "analysis", "of", "the", "APC", "gene", "in", "DNA", "from", "isolated", "blood", "samples.", "Therefore,", "the", "chances", "of", "detecting", "pathogenic", "low-frequency", "APC", "mutations", "that", "are", "present", "only", "in", "a", "small", "fraction", "of", "the", "peripheral", "blood", "cells", "or", "only", "in", "the", "colon", "are", "poor.", "Approximately", "25%", "of", "neurofibromatosis", "type", "2", "(NF2)", "patients", "have", "been", "shown", "to", "be", "cases", "of", "mosaicism", "[44].", "When", "investigating", "NF2", "mutational", "mosaicism", "APC", " ", "mutations", "that", "are", "present", "only", "in", "a", "small", "fraction", "of", "the", "peripheral", "blood", "cells", "or", "only", "in", "the", "colon", "are", "poor.", "Approximately", "25%", "of", "neurofibromatosis", "type", "2", "(NF2)", "patients", "have", "been", "shown", "to", "be", "cases", "of", "mosaicism", "[44].", "When", "investigating", "NF2", "mutational", "mosaicism,", "the", "search", "for", "constitutional", "mutations", "is", "preferably", "carried", "out", "initially", "in", "tumor", "cells.", "Detected", "mutations", "could", "subsequently", "be", "verified", "in", "blood", "leukocyte", "samples.", "However,", "this", "approach", "would", "not", "be", "applicable", "for", "FAP", "mosaisicm", "as", "somatic", "APC", "blood", "APC", " ", "mutational", "mosaicism", "could", "be", "a", "reason", "for", "the", "quite", "large", "number", "of", "de", "novo", "or", "sporadic", "FAP", "cases", "that", "exist", "[23-25,40].", "In", "the", "family", "of", "C107", "the", "mutation", "has", "not", "been", "passed", "on", "to", "the", "offspring", "of", "the", "patient", "and,", "thus,", "this", "appears", "to", "be", "a", "sporadic", "case,", "but,", "generally,", "the", "existence", "of", "mosaicism", "is", "a", "risk", "of", "error", "in", "predictive", "diagnosis", "in", "FAP/AFAP", "families", "[43].", "In", "the", "initial", "stages,", "the", "molecular", "screening", "procedure", "of", "FAP/AFAP", "patients", "uses", "mainly", "PCR-based", "methods", "for", "analysis", "of", "the", "APC", " ", "gene", "in", "DNA", "from", "isolated", "blood", "samples.", "Therefore,", "the", "chances", "of", "detecting", "pathogenic", "low-frequency", "APC", "mutations", "that", "are", "present", "only", "in", "a", "small", "fraction", "of", "the", "peripheral", "blood", "cells", "or", "only", "in", "the", "colon", "are", "poor.", "Approximately", "25%", "of", "neurofibromatosis", "type", "2", "(NF2)", "patients", "have", "been", "shown", "to", "be", "cases", "of", "mosaicism", "[44].", "When", "investigating", "NF2", "mutational", "mosaicism,", "the", "search", "for", "constitutional", "mutations", "is", "preferably", "carried", "out", "initially", "in", "tumor", "cells.", "Detected", "mutations", "could", "subsequently", "be", "verified", "in", "blood", "leukocyte", "samples.", "However,", "this", "approach", "would", "not", "be", "applicable", "for", "FAP", "mosaisicm", "as", "somatic", "APC", "mutations", "are", "frequently", "found", "in", "tumors." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 7, 8, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 3, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
APC mutational mosaicism could be a reason for the quite large number of de novo or sporadic FAP cases that exist [23-25,40]. In the family of C107 the mutation has not been passed on to the offspring of the patient and, thus, this appears to be a sporadic case, but, generally, the existence of mosaicism is a risk of error in predictive diagnosis in FAP/AFAP families [43]. In the initial stages, the molecular screening procedure of FAP/AFAP patients uses mainly PCR-based methods for analysis of the APC gene in DNA from isolated blood samples. Therefore, the chances of detecting pathogenic low-frequency APC mutations that are present only in a small fraction of the peripheral blood cells or only in the colon are poor. Approximately 25% of neurofibromatosis type 2 (NF2) patients have been shown to be cases of mosaicism [44]. When investigating NF2 mutational mosaicism APC mutations that are present only in a small fraction of the peripheral blood cells or only in the colon are poor. Approximately 25% of neurofibromatosis type 2 (NF2) patients have been shown to be cases of mosaicism [44]. When investigating NF2 mutational mosaicism, the search for constitutional mutations is preferably carried out initially in tumor cells. Detected mutations could subsequently be verified in blood leukocyte samples. However, this approach would not be applicable for FAP mosaisicm as somatic APC blood APC mutational mosaicism could be a reason for the quite large number of de novo or sporadic FAP cases that exist [23-25,40]. In the family of C107 the mutation has not been passed on to the offspring of the patient and, thus, this appears to be a sporadic case, but, generally, the existence of mosaicism is a risk of error in predictive diagnosis in FAP/AFAP families [43]. In the initial stages, the molecular screening procedure of FAP/AFAP patients uses mainly PCR-based methods for analysis of the APC gene in DNA from isolated blood samples. Therefore, the chances of detecting pathogenic low-frequency APC mutations that are present only in a small fraction of the peripheral blood cells or only in the colon are poor. Approximately 25% of neurofibromatosis type 2 (NF2) patients have been shown to be cases of mosaicism [44]. When investigating NF2 mutational mosaicism, the search for constitutional mutations is preferably carried out initially in tumor cells. Detected mutations could subsequently be verified in blood leukocyte samples. However, this approach would not be applicable for FAP mosaisicm as somatic APC mutations are frequently found in tumors.
3034663-04-Results-p01
[ "Results", "of", "genotyping", "for", "the", "p.Lys618Ala", "variant", "using", "the", "iPLEX", "Sequenom", "(A)", "and", "sequencing", "(B)", "methods." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Results of genotyping for the p.Lys618Ala variant using the iPLEX Sequenom (A) and sequencing (B) methods.
2386495-04-Results-p02
[ "Three", "patients", "(C107,", "C257,", "and", "C505),", "negative", "for", "mutations", "in", "APC,", "were", "reported", "as", "de", "novo", "cases", "with", "no", "known", "family", "history", "of", "FAP.", "These", "patients", "where", "all", "screened", "for", "APC", "mutations", "present", "as", "low-frequency", "alleles", "using", "SSCP/HD.", "We", "did", "not", "detect", "any", "signs", "of", "low-frequency", "mutations", "in", "patients", "C257", "and", "C505.", "However,", "in", "patient", "C107,", "aberrant", "bands,", "possibly", "originating", "from", "formation", "of", "heteroduplexes,", "was", "detected", "by", "SSCP/HD", "in", "a", "very", "low", "fraction", "of", "her", "blood", "lymphocytes.", "The", "c.2700_2701delTC", "mutation,", "which", "results", "in", "frame", "shift", "at", "codon", "900,", "was", "found", "by", "sequencing", "of", "the", "aberrant", "bands", "excised", "from", "the", "SSCP/HD", "gel", "(Figure", "2A).", "The", "mutation", "was", "detected", "in", "approximately", "one-third", "of", "the", "analyzed", "tumor-derived", "cells", "extracted", "from", "paraffin-embedded", "tissue", "by", "DNA", "sequencing", "(Figure", "2B).", "The", "mutation", "was", "not", "detectable", "at", "all", "in", "the", "sequence", "determination", "of", "DNA", "extracted", "from", "blood", "lymphocytes", "from", "the", "patient", "(Figure", "2C)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Three patients (C107, C257, and C505), negative for mutations in APC, were reported as de novo cases with no known family history of FAP. These patients where all screened for APC mutations present as low-frequency alleles using SSCP/HD. We did not detect any signs of low-frequency mutations in patients C257 and C505. However, in patient C107, aberrant bands, possibly originating from formation of heteroduplexes, was detected by SSCP/HD in a very low fraction of her blood lymphocytes. The c.2700_2701delTC mutation, which results in frame shift at codon 900, was found by sequencing of the aberrant bands excised from the SSCP/HD gel (Figure 2A). The mutation was detected in approximately one-third of the analyzed tumor-derived cells extracted from paraffin-embedded tissue by DNA sequencing (Figure 2B). The mutation was not detectable at all in the sequence determination of DNA extracted from blood lymphocytes from the patient (Figure 2C).
1557864-05-Discussion-p03
[ "The", "relation", "between", "MMR", "deficiency", "and", "platinum-drug", "resistance", "has", "been", "investigated", "in", "only", "a", "few", "in", "vivo", "studies.", "Similarly", "to", "our", "result,", "no", "MSI", "was", "detected", "by", "Mesquita", "et", "al.", "[18]", "who", "studied", "34", "ovarian", "carcinomas", "of", "which", "seven", "did", "not", "respond", "to", "cisplatin/paclitaxel", "therapy.", "So", "the", "resistance", "seen", "in", "these", "seven", "nonresponding", "patients", "was", "also", "not", "associated", "with", "MMR", "seven", "serous", "clear", "cell", " ", "and", "serous", "adenocarcinoma", "adenocarcinoma", "endometrioid", "mucinous", "carcinoma", " ", "tissues", "analyzed", "(Table", "2).", "This", "difference", "in", "the", "distribution", "could", "be", "a", "cause", "for", "the", "wide", "range", "in", "the", "MSI", "frequency", "especially", "since", "it", "has", "been", "suggested", "that", "certain", "histological", "types", "have", "a", "higher", "frequency", "of", "MSI.", "To", "determine", "whether", "there", "is", "a", "relation", "between", "histology", "and", "MSI", "within", "these", "studies,", "we", "looked", "at", "the", "frequency", "of", "MSI", "per", "histological", "type", "for", "the", "628", "patients", "with", "known", "histology", "(Table", "2).", "The", "summary", "of", "these", "studies", "suggests", "that", "the", "frequency", "of", "MSI", "is", "higher", "in", "the", "mucinous", "and", "endometrioid", "adenocarcinoma", "compared", "to", "clear", "cell", "and", "serous", "adenocarcinoma", "(the", "overall", "frequencies", "of", "MSI", "were", "22%,", "16%,", "9%", "and", "8%,", "respectively)", "(Table", "2).", "We", "hypothesize", "that", "mucinous", "and", "endometrioid", "histology", "might", "be", "prone", "to", "a", "higher", "MSI", "frequency", "since", "sporadic", "endometrial", "carcinoma,", "which", "is", "closely", "related", "to", "endometrioid", "ovarian", "cancer,", "has", "a", "MSI", "frequency", "of", "20–30%", "[49-51]", "and", "MSI", "is", "almost", "universal", "present", "in", "the", "colorectal", "tumors", "of", "the", "hereditary", "nonpolyposis", "colon", "cancer", "(HNPCC)", "syndrome", "which", "all", "have", "a", "mucinous", "histological", "type.", "Therefore,", "the", "different", "histology's", "of", "the", "ovarian", "carcinomas", "included", "in", "the", "several", "studies", "seems", "to", "be", "a", "plausible", "cause", "for", "the", "wide", "range", "in", "MSI", "frequency", "reported", "in", "these", "studies." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 21, 11, 17, 3, 4, 0, 0, 0, 1, 1, 3, 19, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The relation between MMR deficiency and platinum-drug resistance has been investigated in only a few in vivo studies. Similarly to our result, no MSI was detected by Mesquita et al. [18] who studied 34 ovarian carcinomas of which seven did not respond to cisplatin/paclitaxel therapy. So the resistance seen in these seven nonresponding patients was also not associated with MMR seven serous clear cell and serous adenocarcinoma adenocarcinoma endometrioid mucinous carcinoma tissues analyzed (Table 2). This difference in the distribution could be a cause for the wide range in the MSI frequency especially since it has been suggested that certain histological types have a higher frequency of MSI. To determine whether there is a relation between histology and MSI within these studies, we looked at the frequency of MSI per histological type for the 628 patients with known histology (Table 2). The summary of these studies suggests that the frequency of MSI is higher in the mucinous and endometrioid adenocarcinoma compared to clear cell and serous adenocarcinoma (the overall frequencies of MSI were 22%, 16%, 9% and 8%, respectively) (Table 2). We hypothesize that mucinous and endometrioid histology might be prone to a higher MSI frequency since sporadic endometrial carcinoma, which is closely related to endometrioid ovarian cancer, has a MSI frequency of 20–30% [49-51] and MSI is almost universal present in the colorectal tumors of the hereditary nonpolyposis colon cancer (HNPCC) syndrome which all have a mucinous histological type. Therefore, the different histology's of the ovarian carcinomas included in the several studies seems to be a plausible cause for the wide range in MSI frequency reported in these studies.
1619718-05-Discussion-p01
[ "The", "adenomas", "in", "this", "study", "were", "grouped", "as", "TAs", "<", " ", "10", "mm,", "TAs", ">", " ", "10", "mm", "and", "TVAs/VAs.", "Overall,", "KRAS", "mutation", "occurred", "in", "26.5%", "of", "adenomas", "while", "BRAF", "mutation", "was", "detected", "in", "only", "4.8%.", "Three", "of", "the", "four", "BRAF", "mutations", "occurred", "in", "adenomas", "that", "also", "had", "KRAS", "mutation.", "It", "is", "well", "established", "that", "BRAF", "and", "KRAS", "mutation", "rarely", "occur", "in", "the", "same", "colorectal", "neoplasm.12,16,30", "Furthermore,", "BRAF", "mutations", "are", "much", "more", "typical", "of", "serrated", "polyps", "than", "adenomas.14,31", "The", "assay", "for", "BRAF", "mutation", "used", "in", "this", "study", "was", "highly", "sensitive", "and", "it", "is", "possible", "that", "the", "mutation", "was", "being", "identified", "in", "normal", "mucosa", "included", "with", "the", "polyp.", "KRAS", "mutation", "may", "occur", "within", "apparently", "normal", " ", "colorectal", "mucosa", "and", "the", "same", "could", "apply", "to", "BRAF.32", "Therefore,", "the", "finding", "of", "BRAF", "mutation", "in", "a", "small", "subset", "of", "adenomas", "could", "be", "spurious", "and", "the", "true", "incidence", "of", "BRAF", "mutation", "in", "colorectal", "adenomas", "could", "be", "lower", "than", "4.8%.", "BRAF", "mutation", "frequencies", "of", "0%14", "and", "3%31", "have", "been", "reported", "in", "other", "series", "of", "colorectal", "adenomas." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The adenomas in this study were grouped as TAs <   10 mm, TAs >   10 mm and TVAs/VAs. Overall, KRAS mutation occurred in 26.5% of adenomas while BRAF mutation was detected in only 4.8%. Three of the four BRAF mutations occurred in adenomas that also had KRAS mutation. It is well established that BRAF and KRAS mutation rarely occur in the same colorectal neoplasm.12,16,30 Furthermore, BRAF mutations are much more typical of serrated polyps than adenomas.14,31 The assay for BRAF mutation used in this study was highly sensitive and it is possible that the mutation was being identified in normal mucosa included with the polyp. KRAS mutation may occur within apparently normal colorectal mucosa and the same could apply to BRAF.32 Therefore, the finding of BRAF mutation in a small subset of adenomas could be spurious and the true incidence of BRAF mutation in colorectal adenomas could be lower than 4.8%. BRAF mutation frequencies of 0%14 and 3%31 have been reported in other series of colorectal adenomas.
1619718-05-Discussion-p02
[ "dysplastic", "serrated", "polyps:", "MP", "and", "SA" ]
[ 0, 0, 0, 0, 0, 0 ]
dysplastic serrated polyps: MP and SA
1619718-01-Abstract-p01
[ "To", "establish", "and", "explain", "the", "pattern", "of", "molecular", "signatures", "across", "colorectal", "polyps." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
To establish and explain the pattern of molecular signatures across colorectal polyps.
1334229-01-Abstract-p01
[ "The", "early", "to", "intermediate", "stages", "of", "the", "majority", "of", "colorectal", "tumours", "are", "thought", "to", "be", "driven", "by", "aberrations", "in", "the", "Wnt", "(APC,", "CTNNB1)", "and", "Ras", "(K-ras)", "pathways.", "A", "smaller", "proportion", "of", "cancers", "shows", "mismatch", "repair", "deficiency.", "The", "aim", "of", "this", "study", "was", "to", "analyse", "the", "co-occurrence", "of", "these", "genetic", "alterations", "in", "relation", "to", "tumour", "and", "patient", "characteristics." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The early to intermediate stages of the majority of colorectal tumours are thought to be driven by aberrations in the Wnt (APC, CTNNB1) and Ras (K-ras) pathways. A smaller proportion of cancers shows mismatch repair deficiency. The aim of this study was to analyse the co-occurrence of these genetic alterations in relation to tumour and patient characteristics.
1557864-01-Abstract-p01
[ "Results" ]
[ 0 ]
Results
1601966-03-Results-p03
[ "Statistics", "on", "expression", "imbalances", "across", "human", "chromosomes." ]
[ 0, 0, 0, 0, 0, 0, 0 ]
Statistics on expression imbalances across human chromosomes.
1334229-01-Abstract-p01
[ "Results" ]
[ 0 ]
Results
1601966-03-Results-p01
[ "Hierarchical", "clustering", "of", "samples", "from", "colorectal", "tumors", "and", "normal", "colon", "epithelia.", "On", "the", "right,", "you", "find", "the", "chromosomal", "localization", "of", "the", "genes", "and", "the", "official", "HUGO", "symbol", "or", "prospective", "Affymetrix", "cluster", "ID.", "On", "the", "top,", "the", "binary", "tree", "of", "tissue", "samples", "based", "on", "gene", "expression", "is", "given.", "The", "tissue", "denominators", "either", "contain", "TR", "for", "tumor", "or", "E", "for", "epithelium", "and", "a", "code", "reflecting", "the", "identity", "of", "each", "patient.", "In", "the", "center,", "the", "expression", "values", "after", "normalization", "have", "been", "color-coded:", "light", "blue", "means", "high", "expression,", "black", "means", "low", "(or", "no)", "expression.", "Note", "that", "only", "a", "representative", "fraction", "of", "the", "514", "genes", "is", "visualized", "here", "(white", "bars", "replace", "some", "portions", "of", "original", "heat", "map).", "The", "right", "cluster", "contains", "only", "samples", "from", "normal", "colon", "epithelia,", "the", "left", "cluster", "is", "composed", "primarily", "of", "tumors", "normal", " ", "tissues", "mainly", "clustered", "together", "with", "matching", "tumor", "samples", "from", "same", "patients.", "This", "suggests", "that", "coalescence", "between", "tumor", "and", "normal", "samples", "from", "the", "same", "patients", "could", "be", "due", "to", "patient-specific", "gene", "expression", "characteristics.", "As", "the", "majority", "of", "normal", "samples", "could", "be", "clearly", "separated", "from", "tumors,", "we", "concluded", "that", "our", "data", "set", "is", "well", "suited", "to", "explore", "differences", "in", "gene", "expression", "between", "normal", "and", "tumor", "cells", "of", "colorectal", "origin." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Hierarchical clustering of samples from colorectal tumors and normal colon epithelia. On the right, you find the chromosomal localization of the genes and the official HUGO symbol or prospective Affymetrix cluster ID. On the top, the binary tree of tissue samples based on gene expression is given. The tissue denominators either contain TR for tumor or E for epithelium and a code reflecting the identity of each patient. In the center, the expression values after normalization have been color-coded: light blue means high expression, black means low (or no) expression. Note that only a representative fraction of the 514 genes is visualized here (white bars replace some portions of original heat map). The right cluster contains only samples from normal colon epithelia, the left cluster is composed primarily of tumors normal tissues mainly clustered together with matching tumor samples from same patients. This suggests that coalescence between tumor and normal samples from the same patients could be due to patient-specific gene expression characteristics. As the majority of normal samples could be clearly separated from tumors, we concluded that our data set is well suited to explore differences in gene expression between normal and tumor cells of colorectal origin.
2386495-01-Abstract-p01
[ "Results" ]
[ 0 ]
Results
2386495-02-Background-p01
[ "The", "majority", "of", "germline", "APC", "mutations", "identified", "in", "FAP", "families", "cause", "truncations", "in", "this", "multifunctional", "protein", "[6,7].", "The", "APC", "truncations", "most", "often", "occur", "as", "the", "result", "of", "nonsense", "APC", "mutations", "or", "frameshifts", "caused", "by", "small", "deletions/insertions.", "Large", "APC", "deletions", "are", "found", "in", "a", "limited", "number", "of", "FAP", "cases.", "By", "using", "methods", "such", "as", "quantitative", "real-time", "PCR", "(polymerase", "chain", "reaction)", "or", "MLPA", "(multiplex", "ligation-dependent", "probe", "amplification)", "rather", "than", "conventional", "mutation-detection", "techniques,", "we", "can", "achieve", "higher", "detection", "rates", "of", "large", "deletions", "[8-12].", "The", "number", "of", "reported", "characterized", "APC", "splice-site", "mutations", "is", "comparatively", "low", "[13-17].", "Approximately", "10–15%", "of", "the", "FAP", "patients", "could", "have", "a", "reduced", "or", "absent", "APC", "expression", "[18].", "The", "cause", "of", "the", "reduced", "expression", "is", "not", "known", "but", "the", "patients", "show", "a", "similar", "phenotype", "to", "those", "with", "an", "identified", "truncating", "APC", "mutation", "[19-21].", "It", "has", "been", "shown", "that", "a", "decrease", "of", "approximately", "50%", "of", "the", "expression", "of", "an", "allele", "can", "result", "in", "a", "predisposition", "to", "FAP", "[20].", "Germline", "APC-mutation", "mosaicism", "in", "FAP", "patients", "has", "been", "reported", "[22-25]", "but", "is", "not", "generally", "included", "in", "the", "mutation", "screening", "procedure", "provided", "by", "most", "labs", "owing", "to", "the", "technical", "difficulties", "encountered", "with", "these", "analyses." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The majority of germline APC mutations identified in FAP families cause truncations in this multifunctional protein [6,7]. The APC truncations most often occur as the result of nonsense APC mutations or frameshifts caused by small deletions/insertions. Large APC deletions are found in a limited number of FAP cases. By using methods such as quantitative real-time PCR (polymerase chain reaction) or MLPA (multiplex ligation-dependent probe amplification) rather than conventional mutation-detection techniques, we can achieve higher detection rates of large deletions [8-12]. The number of reported characterized APC splice-site mutations is comparatively low [13-17]. Approximately 10–15% of the FAP patients could have a reduced or absent APC expression [18]. The cause of the reduced expression is not known but the patients show a similar phenotype to those with an identified truncating APC mutation [19-21]. It has been shown that a decrease of approximately 50% of the expression of an allele can result in a predisposition to FAP [20]. Germline APC-mutation mosaicism in FAP patients has been reported [22-25] but is not generally included in the mutation screening procedure provided by most labs owing to the technical difficulties encountered with these analyses.
1360090-03-Results-p01
[ "BRAF", "mutations", "showed", "no", "association", "with", "TP53", "mutations", "and", "were", "mutually", "exclusive", "with", "the", "presence", "of", "KRAS", "mutations", "(Table", "2).", "In", "contrast,", "BRAF", "mutations", "were", "approximately", "10-fold", "more", "frequent", "in", "MSI+", "and", "CIMP+", "tumors", "compared", "to", "tumors", "without", "these", "phenotypes.", "A", "strong", "association", "was", "also", "seen", "with", "methylation", "of", "the", "MLH1", "gene", "promoter", "and", "in", "particular", "with", "methylation", "of", "its", "proximal", "region.", "We", "have", "previously", "examined", "the", "methylation", "status", "of", "7", "different", "CpG", "islands", "in", "this", "CRC", "series", "[18].", "The", "mean", "number", "of", "these", "methylated", "sites", "was", "3-fold", "higher", "in", "tumors", "with", "BRAF", "mutation", "compared", "to", "those", "without", "(2.6", "±", "1.7", "vs", "0.8", "±", "1.0;", "P", "<", "0.001).", "Multivariate", "analysis", "revealed", "that", "MSI+", "was", "the", "only", "significant", "independent", "predictor", "of", "BRAF", "mutation", "(RR", "=", "6.3,", "95%CI", "[1.2–32.3];", "P", "=", "0.028)", "in", "a", "model", "that", "included", "CIMP+,", "tumor", "site,", "histological", "grade,", "presence", "of", "infiltrating", "lymphocytes", "and", "mucinous", "appearance." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
BRAF mutations showed no association with TP53 mutations and were mutually exclusive with the presence of KRAS mutations (Table 2). In contrast, BRAF mutations were approximately 10-fold more frequent in MSI+ and CIMP+ tumors compared to tumors without these phenotypes. A strong association was also seen with methylation of the MLH1 gene promoter and in particular with methylation of its proximal region. We have previously examined the methylation status of 7 different CpG islands in this CRC series [18]. The mean number of these methylated sites was 3-fold higher in tumors with BRAF mutation compared to those without (2.6 ± 1.7 vs 0.8 ± 1.0; P < 0.001). Multivariate analysis revealed that MSI+ was the only significant independent predictor of BRAF mutation (RR = 6.3, 95%CI [1.2–32.3]; P = 0.028) in a model that included CIMP+, tumor site, histological grade, presence of infiltrating lymphocytes and mucinous appearance.
1557864-02-Background-p01
[ "Inactivation", "of", "MMR", "leads", "to", "the", "occurrence", "of", "unrepaired", "deletions", "in", "mono-", "and", "dinucleotide", "repeats", "resulting", "in", "variable", "lengths", "of", "these", "repeats.", "This", "is", "called", "microsatellite", "instability", "(MSI)", "and", "MSI", "is", "therefore", "used", "as", "a", "marker", "for", "MMR", "deficiency.", "MSI", "can", "be", "caused", "by", "genetic", "or", "epigenetic", "inactivation", "of", "several", "genes", "involved", "in", "MMR.", "Mouse", "knockout", "models", "have", "demonstrated", "that", "MSH2-/-,", "MSH3-/-,", "MLH1-/-", "and", "PMS2-/-", "leads", "to", "a", "high", "frequency", "of", "MSI", "while", "MSH6-/-", "and", "PMS1-/-", "cause", "a", "low", "frequency", "(reviewed", "by", "Wei", "et", "al.", "[10]).", "However,", "in", "hereditary", "nonpolyposis", "colon", "cancer", "(HNPCC)", "families", "(which", "are", "known", "to", "have", "a", "high", "frequency", "of", "MSI", "cancer", "Ovarian", " ", "cancer", "is", "the", "leading", "cause", "of", "death", "from", "gynecological", "cancer", "in", "the", "Western", "world", "[1].", "The", "treatment", "of", "ovarian", "adenocarcinoma", "has", "improved", "over", "the", "last", "20", "years", "owing", "to", "the", "combined", "treatment", "of", "cytoreductive", "surgery", "and", "chemotherapy", "[2].", "Although", "the", "response", "of", "the", "primary", "tumor", "to", "taxane", "and", "platinum-based", "chemotherapy", "is", "high,", "about", "20%", "of", "patients", "never", "achieve", "a", "clinical", "response", "and", "the", "majority", "of", "the", "patients", "will", "relapse", "and", "eventually", "die", "of", "drug-resistant", "disease", "[3]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 19, 1, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Inactivation of MMR leads to the occurrence of unrepaired deletions in mono- and dinucleotide repeats resulting in variable lengths of these repeats. This is called microsatellite instability (MSI) and MSI is therefore used as a marker for MMR deficiency. MSI can be caused by genetic or epigenetic inactivation of several genes involved in MMR. Mouse knockout models have demonstrated that MSH2-/-, MSH3-/-, MLH1-/- and PMS2-/- leads to a high frequency of MSI while MSH6-/- and PMS1-/- cause a low frequency (reviewed by Wei et al. [10]). However, in hereditary nonpolyposis colon cancer (HNPCC) families (which are known to have a high frequency of MSI cancer Ovarian cancer is the leading cause of death from gynecological cancer in the Western world [1]. The treatment of ovarian adenocarcinoma has improved over the last 20 years owing to the combined treatment of cytoreductive surgery and chemotherapy [2]. Although the response of the primary tumor to taxane and platinum-based chemotherapy is high, about 20% of patients never achieve a clinical response and the majority of the patients will relapse and eventually die of drug-resistant disease [3].
1266026-04-Results-p01
[ "Duke's", "stage", "and", "age", "at", "clinical", "presentation", "(Figure", "1B)", "were", "documented", "for", "884", "of", "the", "895", "MSI-", "sporadic", "cancers", "(Table", "1).", "Average", "ages", "were", "68.6", "years", "for", "stage", "A,", "69.0", "years", "for", "stage", "B,", "65.2", "years", "for", "stage", "C,", "and", "65.4", "years", "for", "stage", "D.", "The", "most", "likely", "numbers", "of", "oncogenic", "mutations", "were", "seven", "for", "stage", "A", "cancers,", "eight", "for", "stage", "B", "cancers,", "and", "six", "for", "stage", "C", "or", "D", "cancers", "(Table", "1)." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Duke's stage and age at clinical presentation (Figure 1B) were documented for 884 of the 895 MSI- sporadic cancers (Table 1). Average ages were 68.6 years for stage A, 69.0 years for stage B, 65.2 years for stage C, and 65.4 years for stage D. The most likely numbers of oncogenic mutations were seven for stage A cancers, eight for stage B cancers, and six for stage C or D cancers (Table 1).
1601966-03-Results-p10
[ "Down-regulation", "of", "mRNA", "expression", "in", "human", "chromosomal", "region", "18q21.2-18q23", "–", "the", "BCL2", "region", "(patient", "counts", "with", "coordinate", "up-regulation).", "Grayscale", "cross-comparison", "plot", "of", "up-regulation", "patterns", "across", "patients", "(analogous", "to", "Figures", "7,", "10,", "13).", "View", "this", "plot", "in", "conjunction", "with", "Figures", "24", "and", "26." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Down-regulation of mRNA expression in human chromosomal region 18q21.2-18q23 – the BCL2 region (patient counts with coordinate up-regulation). Grayscale cross-comparison plot of up-regulation patterns across patients (analogous to Figures 7, 10, 13). View this plot in conjunction with Figures 24 and 26.
2275286-03-Methods-p01
[ "Patients" ]
[ 0 ]
Patients
1601966-03-Results-p04
[ "20q11.22-q11.23" ]
[ 0 ]
20q11.22-q11.23
1266026-05-Discussion-p03
[ "**", "IGNORE", "LINE", "**" ]
[ 0, 0, 0, 0 ]
** IGNORE LINE **
3034663-04-Results-p01
[ "There", "were", "no", "significant", "associations", "in", "the", "case-control", "and", "case-case", "studies", "(80%", "detection", "power,", "OR", "=", "3.0;", "two-sided", "test,", "alpha", "level", "=", "5%)", "(Table", "2)", "and", "no", "statistically", "significant", "associations", "when", "the", "OR", "was", "adjusted", "for", "age", "and", "sex." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
There were no significant associations in the case-control and case-case studies (80% detection power, OR = 3.0; two-sided test, alpha level = 5%) (Table 2) and no statistically significant associations when the OR was adjusted for age and sex.
1373649-03-Methods-p01
[ "The", "early", "onset", "of", "the", "colon", "cancer", "in", "the", "proband", " ", "and", "the", "study", "of", "the", "family's", "pedigree", "(fig.", "1),", "that", "fulfill", "the", "strict", "Amsterdam-1", "criteria,", "prompted", "genetic", "analysis", "with", "suspicion", "of", "HNPCC.", "They", "were", "informed", "about", "the", "risks,", "benefits", "and", "limitations", "of", "the", "study", "protocol." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 9, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
The early onset of the colon cancer in the proband and the study of the family's pedigree (fig. 1), that fulfill the strict Amsterdam-1 criteria, prompted genetic analysis with suspicion of HNPCC. They were informed about the risks, benefits and limitations of the study protocol.
1266026-05-Discussion-p02
[ "Multistage", "models", "are", "mechanistically", "different", "from", "tumor", "progression", "models", "and", "more", "consistent", "with", "a", "hypothesis", "that", "mutations", "acquired", "early", "during", "progression", "help", "determine", "extent", "of", "invasion", "(Figure", "3).", "Mutations", "sequentially", "accumulate", "before", "transformation", "in", "both", "models,", "but", "the", "adenoma-cancer", "sequence", "suggests", "most", "cancer", "mutations", "start", "to", "accumulate", "after", "the", "age", "of", "50", "years", "in", "adenomas", "[7].", "Such", "tumor", "progression", "imposes", "purpose", "to", "early", "mutations", "because", "each", "additional", "mutation", "confers", "incremental", "changes", "to", "a", "non-invasive", "adenoma", " ", "phenotype.", "Therefore,", "tumor", "progression", "models", "would", "likely", "differ", "between", "MSI+", "and", "MSI-", "cancers", "because", "their", "biology", "and", "types", "of", "mutations", "are", "quite", "different", "[7,8]." ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
Multistage models are mechanistically different from tumor progression models and more consistent with a hypothesis that mutations acquired early during progression help determine extent of invasion (Figure 3). Mutations sequentially accumulate before transformation in both models, but the adenoma-cancer sequence suggests most cancer mutations start to accumulate after the age of 50 years in adenomas [7]. Such tumor progression imposes purpose to early mutations because each additional mutation confers incremental changes to a non-invasive adenoma phenotype. Therefore, tumor progression models would likely differ between MSI+ and MSI- cancers because their biology and types of mutations are quite different [7,8].
1334229-03-Methods-p02
[ "CTNNB1", "mutation", "analysis" ]
[ 0, 0, 0 ]
CTNNB1 mutation analysis
1266026-03-Methods-p01
[ "Quantitative", "analysis" ]
[ 0, 0 ]
Quantitative analysis